Stapled peptides and methods thereof
Patent Information
- Application Number
- PCT/US2026/022175
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-10-22
- Filing Date
- 2026-04-02
- Publication Date
- 2026-11-12
AI Technical Summary
Current treatments for conditions associated with ERG, such as prostate cancer, are inadequate in reducing ERG polypeptide levels and inhibiting tumor growth effectively.
Development of stapled peptides that bind to ERG and E3 ligases to promote ubiquitination and degradation of ERG polypeptides, thereby inhibiting cell proliferation and tumor growth.
The stapled peptides effectively reduce ERG polypeptide levels, inhibit tumor growth, and modulate ERG target gene expression, providing therapeutic benefits for conditions like prostate cancer.
Abstract
Description
Attorney Docket Number: 2012675-0444STAPLED PEPTIDES AND METHODS THEREOFCROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority to United States Provisional Application Nos. 63 / 782,558, filed April 2, 2025, 63 / 793,888, filed April 24, 2025, and 63 / 903,833. filed October 22, 2025. the entirety of each of which is incorporated herein by reference.BACKGROUND
[0002] Stapled peptides are useful for various applications. For example, as biologically active agents, they can be utilized to modulate various biological functions.SUMMARY
[0003] Among other things, the present disclosure provides technologies (e.g., agents (e.g., those that are or comprise peptides, in many embodiments, stapled peptides), compositions, methods, etc.) for modulating various biological functions of ERG. In some embodiments, the present disclosure provides technologies that can reduce levels of ERG polypeptides. In some embodiments, the present disclosure provides technologies for degrading ERG polypeptides. In some embodiments, provided technologies are useful for treating various conditions, diseases or disorders, e.g., those associated with ERG (e.g., prostate cancer comprising ERG-TMPRSS2 fusion).
[0004] In some embodiments, the present disclosure provides agents that comprise a target binding moiety that can bind ERG, a linker, and an E3 ligase binding moiety. In some embodiments, a target binding moiety is or comprises a stapled peptide moiety.
[0005] In some embodiments, the present disclosure provides an agent, wherein the agent has the structure of:TBM-L°-LBM,or a salt thereof, wherein each variable is independently as described herein. In some embodiments, target binding moiety is or comprises a stapled peptide moiety and can bind to ERG, and LBM can bind an E3 ligase (e.g., CRBN, VHL, etc.).
[0006] In some embodiments, the present disclosure provides technologies for modulating one or more functions of ERG. In some embodiments, the present disclosure provides various agents, e.g., agents that arc or comprise peptides, in many instances stapled peptides, that can bind to ERG and modulate its functions. In some embodiments, provided agents can reduce ERG polypeptide levels. In some embodiments, provided technologies can reduce ERG polypeptide levels, inhibit proliferation, and / or inhibit tumor growth, e.g., when assessed in cells and / or animal models (e.g., CDX and PDX models).
[0007] In some embodiments, provided agents are useful for reducing ERG polypeptide levels. In some embodiments, provided agents are useful for reducing ERG polypeptide levels via interactions with an E3 Page 1 of 6713424615vlAttorney Docket Number: 2012675-0444ligase. In some embodiments, provided agents are useful for reducing ERG polypeptide levels by binding to ERG and an E3 ligase. In some embodiments, provided agents are useful for reducing ERG polypeptide levels by binding to ERG through a peptide moiety, often a stapled peptide moiety, and an E3 ligase through a ligase binding moiety. In some embodiments, provided agents are useful for reducing ERG polypeptide levels via interactions with an E3 ligase. In some embodiments, provided agents are useful for promoting interactions between ERG and an E3 ligase. In some embodiments, provided agents are useful for promoting interactions between ERG and an E3 ligase by binding to ERG through a peptide moiety, often a stapled peptide moiety, and an E3 ligase through a ligase binding moiety.
[0008] In some embodiments, the present disclosure provides technologies for increasing ubiquitination level of a target polypeptide, e.g., an ERG polypeptide, comprising contacting the target polypeptide with an agent described herein. In some embodiments, the present disclosure provides technologies for reducing level of a target polypeptide, e.g., an ERG polypeptide, comprising contacting the target polypeptide with an agent described herein.
[0009] In some embodiments, the present disclosure provides technologies for reducing cell proliferation, invasion, or migration. In some embodiments, the present disclosure provides technologies for reducing cell proliferation, invasion, or migration in a system, comprising contacting the system with an agent described herein. In some embodiments, provided agents can reduce cell proliferation, invasion, or migration.
[0010] In some embodiments, the present disclosure provides technologies for providing cell cycle arrest. In some embodiments, the present disclosure provides technologies for providing cell cycle arrest in a system, comprising contacting the system with an agent described herein. In some embodiments, provided agents can provide cell cycle arrest.
[0011] In some embodiments, the present disclosure provides technologies for modulating ERG target gene expression. In some embodiments, the present disclosure provides technologies for modulating ERG target gene expression in a system, comprising contacting the system with an agent described herein. In some embodiments, provided agents can modulate ERG target gene expression.
[0012] In some embodiments, the present disclosure provides technologies for inhibiting tumor growth. In some embodiments, the present disclosure provides technologies for inhibiting tumor growth in a system, comprising contacting the system with an agent described herein. In some embodiments, provided agents can inhibit tumor growth.
[0013] In some embodiments, provided technologies are useful for preventing or treating various conditions, disorders or diseases including cancer. In some embodiments, the present disclosure provides methods for treating or preventing a condition, disorder or disease associated with ERG. comprising administering to a subject suffered therefrom or susceptible thereto a provided agent or a pharmaceutically acceptable salt thereof. In some embodiments, a condition, disorder or disease is prostate cancer. In some embodiments, a condition, disorder or disease is metastatic prostate cancer. In some embodiments, a Page 2 of 6713424615vlAttorney Docket Number: 2012675-0444condition, disorder or disease is castration-resistant prostate cancer (CRPC). In some embodiments, a condition, disorder or disease is metastatic CRPC. In some embodiments, a tumor of a prostate cancer may comprise an ERG fusion mutation. In some embodiments,, a tumor of a prostate cancer may comprise a TMPRSS2-ERG fusion mutation. In some embodiments, an agent is administered as a pharmaceutical composition. In some embodiments, the present disclosure provides pharmaceutical compositions which comprise or deliver a provided agent or a pharmaceutically acceptable salt thereof.
[0014] In some embodiments, a target binding moiety is - [PTBM], wherein PTBMis or comprises a peptide, e.g., a stapled peptide. In some embodiments, PTBMis a peptide. In some embodiments, PTBMis or comprises a stapled peptide. In some embodiments, PTBMcomprises a stapled peptide. In some embodiments, PTBMis a stapled peptide.
[0015] In some embodiments, a peptide, e.g., PTBM, is or comprises a peptide comprising:X1X2X3X4X5X6X7X8X9X10,wherein:each of X1, X2, X3, X4, X5, X6, X7, X8, X9, and X10is independently an amino acid residue.
[0016] In some embodiments, a peptide, e.g., PTBM, is or comprises a peptide comprising:X'X^X^X^X^X’^X^X^X14,wherein:each of X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12, X13, and X14is independently an amino acid residue.
[0017] In some embodiments, a peptide, e.g., PTBM, is or comprises a peptide comprising:[X]pX1X2X3X4X5X6X7X8X9X10[X11]p11[X12]p12[X13]p13[X14]p14[X15]p15[X16]p16[X17]p17[X18]p18[X]p', wherein:each of p11, p12, p13, p14, p15, p16, p17 and p18 is independently 0 or 1;each of p and p’ is independently 0-10;each of X, X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12, X13, X14, X15, X16, X17and X18is independently an amino acid residue.
[0018] In some embodiments, a peptide, e.g., PTBM, is or comprisesRN-[X]pX1X2X3X4X5X6X7X8X9X10[X11]p11[X12]p12[X13]p13[X14]p14[X15]p15[X16]p16[X17]p17[X18]p18[X]p’-Rc, wherein each variable is independently as described herein.
[0019] In some embodiments, a peptide, e.g., PTBM, is or comprises X1X2X3X4X5X6X7X8X9X10[X11]p11[X12]p12[X13]p13[X14]p14[X15]p15[X16]p16[X17]p17[X18]p18[X19]p19[X20]p20[X21]p21[X22]p22[X23]p23, wherein each of p11, p12, p13, p14, p15, p16, p17, p18, p19, p20, p21, p22, and p23 is independently 0 or 1, and each of X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12, X13, X14, X15, X16, X17, X18, X19, X20, X21, X22, and X23is independently an amino acid residue as described herein.
[0020] In some embodiments, a peptide is stapled.
[0021] In some embodiments, one or more of amino acid residues (e.g., X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12, X13, X14, X15, X16, X17, X18, X19, X20, X21, X22, X23, etc.) is independently a D-amino acid Page 3 of 6713424615vlAttorney Docket Number: 2012675-0444residue. In some embodiments, each of X1, X2, X3, X4, X5, X6, X7, X8, X9, and X10is independently a D-amino acid residue. In some embodiments, each of X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12, X13, and X14is independently a D-amino acid residue. In some embodiments, each of X, X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12, X13, X14, X15, X16, X17and X18is independently a D-amino acid residue. In some embodiments, each of X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12, X13, X14, X15, X16, X17, X18, X19, X20, X21, X22, and X23is independently a D-amino acid residue.
[0022] In some embodiments, the present disclosure provides an agent comprising an E3 ligase binding moiety. In some embodiments, LBM is an E3 ligase binding moiety. Various E3 ligase binding moieties are reported and can be utilized in accordance with the present disclosure. In some embodiments, an E3 ligase is CRBN. In some embodiments, an E3 ligase is VHL.
[0023] In some embodiments, an agent has a molecular mass of no more than about 5000 Daltons. In some embodiments, it is no more than about 2500, 3000, 3500, 4000, 4500 or 5000 Daltons. In some embodiments, it is no more than about 2500 Daltons. In some embodiments, it is no more than about 3000 Daltons. In some embodiments, it is no more than about 3500 Daltons. In some embodiments, it is no more than about 4000 Daltons. In some embodiments, it is no more than about 500 Daltons.
[0024] In some embodiments, the present disclosure provides various technologies, e.g., reagents methods, etc., for preparing, characterizing, assessing and using provided agents and compositions thereof. In some embodiments, the present disclosure provides, e.g., methods, reagents and / or systems for identifying, characterizing and / or assessing provided agents and use thereof (e.g., as therapeutic or diagnostic agents).
[0025] In some embodiments, the present disclosure provides pharmaceutical compositions comprising or delivering a provided agent and a pharmaceutical acceptable carrier. In some embodiments, a provided agent is in a pharmaceutically acceptable salt form. In some embodiments, a composition comprises a pharmaceutically acceptable salt form an agent. In some embodiments, in various compositions and methods, agents are provided as pharmaceutically acceptable salt forms.
[0026] In some embodiments, the present disclosure provides methods for modulating ERG and E3 ligase interaction. In some embodiments, the present disclosure provides methods for modulating ERG and E3 ligase interaction, comprising contacting ERG with a provided agent. In some embodiments, the present disclosure provides methods for modulating ERG and E3 ligase interaction in a system comprising ERG and an E3 ligase, comprising administering or delivering to the system a provided agent. In some embodiments, the present disclosure provides methods for modulating ERG and E3 ligase interaction in a system expressing ERG and an E3 ligase, comprising administering or delivering to the system a provided agent. In some embodiments, interaction between ERG and an E3 ligase is increased. In some embodiments, interactions between ERG and an E3 ligase is promoted.
[0027] In some embodiments, the present disclosure provides methods for inducing degradation of ERG. In some embodiments, the present disclosure provides methods for inducing degradation of ERG, comprising contacting ERG with a provided agent. In some embodiments, the present disclosure provides methods for Page 4 of 6713424615vlAttorney Docket Number: 2012675-0444inducing degradation of ERG in a system comprising ERG and an E3 ligase, comprising administering or delivering to tire system a provided agent. In some embodiments, the present disclosure provides methods for inducing degradation of ERG in a system expressing ERG and an E3 ligase, comprising administering or delivering to the system a provided agent. In some embodiments, the rate of ERG degradation in a system is increased. In some embodiments, levels of ERG in a system are reduced.
[0028] In some embodiments, the present disclosure provides methods for inhibiting cell proliferation, comprising administering or delivering to a population of cells a provided agent. In some embodiments, the present disclosure provides methods for inhibiting cell proliferation in a system, comprising administering or delivering to the system a provided agent. In some embodiments, the present disclosure provides methods for inhibiting cell growth, comprising administering or delivering to a population of cells a provided agent. In some embodiments, the present disclosure provides methods for inhibiting cell grow th in a system, comprising administering or delivering to the system a provided agent. In some embodiments, such cell proliferation is ERG dependent.
[0029] In some embodiments, a system is in vitro. In some embodiments, a system is ex vivo. In some embodiments, a system is in vivo. In some embodiments, a system is or comprise a cell. In some embodiments, a system is or comprises a tissue. In some embodiments, a system is or comprises an organ. In some embodiments, a system is or comprises an organism. In some embodiments, a system is an animal. In some embodiments, a system is human. In some embodiments, a system is or comprises cells, tissues or organs associated with a condition, disorder or disease. In some embodiments, a system is or comprises cancer cells.
[0030] In some embodiments, the present disclosure provides methods for preventing conditions, disorders or diseases. In some embodiments, the present disclosure provides methods for reducing risks of conditions, disorders or diseases. In some embodiments, the present disclosure provides methods for preventing a condition, disorder or disease, comprising administering or delivering to a subject susceptible thereto an agent of the present disclosure. In some embodiments, the present disclosure provides methods for reducing risk of a condition, disorder or disease, comprising administering or delivering to a subject susceptible thereto an agent of the present disclosure. In some embodiments, the present disclosure provides methods for reducing risks of a condition, disorder or disease in a population, comprising administering or delivering to a population of subjects susceptible thereto an agent of the present disclosure. In some embodiments, the present disclosure provides methods for treating conditions, disorders or diseases. In some embodiments, the present disclosure provides methods for treating a condition, disorder or disease, comprising administering or delivering to a subject suffering therefrom an agent of the present disclosure. In some embodiments, a symptom is reduced, removed or prevented. In some embodiments, one or more parameters for assessing a condition, disorder or disease are improved. In some embodiments, survival of subjects are extended. As appreciated by those skilled in the art, in some embodiments, prevention, reduced risks, and / or effects of treatment may be assessed through clinical trials and may be observed in subject Page 5 of 6713424615vlAttorney Docket Number: 2012675-0444populations. In some embodiments, a condition, disorder or disease is cancer. In some embodiments, a condition, disorder or disease is associated with ERG. In some embodiments, a condition, disorder or disease is bladder cancer. In some embodiments, a condition, disorder or disease is endometrial cancer. In some embodiments, a condition, disorder or disease is adrenocortical carcinoma. In some embodiments, a condition, disorder or disease is gastric cancer. In some embodiments, a condition, disorder or disease is lung cancer. In some embodiments, a condition, disorder or disease is melanoma. In some embodiments, a condition, disorder or disease is esophageal cancer. In some embodiments, a condition, disorder or disease is colorectal cancer. In some embodiments, a cancer is liver cancer. In some embodiments, a cancer is prostate cancer. In some embodiments, a cancer is breast cancer. In some embodiments, a cancer is endometrial cancer. It is reported that an estimated 40-50% of all prostate cancers harbor TMPRSS2-ERG fusion, which according to some reports can lead to androgen receptor (AR)-driven expression of the oncogene ERG. In some embodiments, a condition, disorder, or disease is associated with TMPRSS2-ERG fusion mutations. In some embodiments, a condition, disorder, or disease is associated with TMPRSS2-ERG fusion proteins. In some embodiments, a condition, disorder, or disease is associated with expression of TMPRSS2-ERG fusion proteins.
[0031] In some embodiments, agents are administered as pharmaceutical compositions that comprise or deliver such agents. In some embodiments, agents are provided and / or delivered in pharmaceutically acceptable salt forms. In some embodiments, in a composition (e.g., a liquid composition of certain pH) an agent may exist in various forms including various pharmaceutically acceptable salt forms.
[0032] In some embodiments, a provided agent is utilized in combination with a second therapy. In some embodiments, a provided agent is utilized in combination with a second therapeutic agent. In some embodiments, a second therapy or therapeutic agent is administered prior to an administration or delivery of a provided agent. In some embodiments, a second therapy or therapeutic agent is administered at about the same time as an administration or deliver} of a provided agent. In some embodiments, a second therapy or therapeutic agent is administered subsequently to an administration or deli ven of a provided agent. In some embodiments, a subject is exposed to both a provided agent and a second therapeutic agent. In some embodiments, a subject is exposed to a therapeutic effect of a provided agent and a therapeutic effect of a second therapeutic agent. In some embodiments, a second therapy is or comprises surgery. In some embodiments, a second therapy is or comprises radiation therapy. In some embodiments, a second therapy is or comprises immunotherapy. In some embodiments, a second therapeutic agent is or comprises a drug. In some embodiments, a second therapeutic agent is or comprises a cancer drug. In some embodiments, a second therapeutic agent is or comprises a chemotherapeutic agent. In some embodiments, a second therapeutic agent is or comprises a honnone therapy agent. In some embodiments, a second therapeutic agent is or comprises a kinase inhibitor. In some embodiments, a second therapeutic agent is or comprises a checkpoint inhibitor (e.g., antibodies against PD-1, PD-L1, CTLA-4, etc.). In some embodiments, a second therapeutic agent is or comprises ARPI. In some embodiments, a second therapeutic agent is or comprises Page 6 of 6713424615vlAttorney Docket Number: 2012675-0444enzalutamide. In some embodiments, a second therapeutic agent is or comprises apalutamide. In some embodiments, a second therapeutic agent is or comprises darolutamide. In some embodiments, a second therapeutic agent is or comprises abiraterone. In some embodiments, a second therapeutic agent is or comprises ARV-110 (bavdegalutamide). In some embodiments, a second therapeutic agent is or comprises ARV-766 (luxdegalutamide). In some embodiments, a second therapeutic agent is or comprises BMS-986365 (gridegalutamide). In some embodiments, a second therapeutic agent is or comprises GDC-2992. In some embodiments, a second therapeutic agent is or comprises AZD 9750. In some embodiments, a second therapeutic agent is or comprises an epigenetic target inhibitor (c.g., PRC2 (EZH2 / EED)). In some embodiments, a second therapeutic agent is or comprises a PRC2 inhibitor.
[0033] In some embodiments, a provide agent can be administered with lower unit dose and / or total dose compared to being used alone. In some embodiments, a second agent can be administered with lower unit dose and / or total dose compared to being used alone. In some embodiments, one or more side effects associated with administration of a provided agent and / or a second therapy or therapeutic agent are reduced. In some embodiments, a combination therapy provides improved results, c.g., when compared to each agent utilized individually. In some embodiments, a combination therapy achieves one or more better results, e.g., when compared to each agent utilized individually.
[0034] Further description of certain embodiments of provided technologies is presented below.BRIEF DESCRIPTION OF THE DRAWING
[0035] Figure 1. Provided technologies can reduce levels of ERG polypeptide. [Helicon] is an agent comprising a stapled peptide and can bind to ERG and an E3 ligase (Agent 1). Assessment was perfonned in VCaP cells. Bort is Bortezomib.
[0036] Figure 2. Provided technologies can reduce levels of ERG polypeptides. Helicon is an agent comprising a stapled peptide and can bind to ERG and an E3 ligase (Agent 1). As shown, when the E3 ligase was knocked down, reduction of ERG polypeptide level by Helicon was reduced. Assessment was performed in VCaP cells.
[0037] Figure 3. Provided technologies can reduce levels of ERG polypeptides. Helicon is an agent comprising a stapled peptide and can bind to ERG and an E3 ligase (Agent 1). As shown, in the presence of MLN4924, reduction of ERG polypeptide level by Helicon was reduced. Assessment was performed in VCaP cells.
[0038] Figure 4. Provided technologies can reduce levels of ERG polypeptides. Helicon is an agent comprising a stapled peptide and can bind to ERG and an E3 ligase (Agent 1). As shown, in the presence of an E3 ligand, reduction of ERG polypeptide level by Helicon was reduced. Assessment was performed in VCaP cells.
[0039] Figure 5. Provided technologies can reduce levels of ERG polypeptides in vivo. Agent 2 is an agent comprising a stapled peptide and can bind to ERG and an E3 ligase. Assessment was performed in a Page 7 of 6713424615vlAttorney Docket Number: 2012675-0444VCaP xenograft mouse model.
[0040] Figure 6. Provided technologies can inhibit tumor grow th in vivo. Agent 3 is an agent comprising a stapled peptide and can bind to ERG and an E3 ligase. Assessment was perfonned in a VCaP xenograft mouse model.
[0041] Figure 7A and Figure 7B. Prostate cancer VCaP cells are sensitive to loss of ERG. VCaP cells stably expressing pLKO-Tet-on-puro with either Non-targeting(NT) shRNAor ERG shRNA were grown in with 200 ng / mL doxycycline. Assessment was perfonned by Western Blot at 7 days (Figure 7A) and Colony Formation Assay at 21 days (Figure 7B). In Figure 7B, vehicle was ethanol, N=3, *p<0.05, one-way ANOVA.
[0042] Figure 8. Provided technologies can target ERG. As demonstrated herein, nanomolar affinity can be achieved in assessment by SPR.
[0043] Figure 9. Provided technologies can reduce levels of ERG polypeptides. Certain data from an REH-FIiBit assessment were presented. Vehicle w'as DMSO. N = 3. Data are shown as mean ± S. D.
[0044] Figure 10. Provided technologies can reduce ERG target gene expression. Assessment was performed by qPCR in VCaP cells after 24 h. N = 3, all data shown as mean ± S. D.
[0045] Figure 11. Provided technologies can reduce viability of cancer cells and provide exhibit antiproliferative effects. Assessment was performed in VCaP cells exposed to 10 nM DHT + an agent after 14 days. N = 3, all data shown as mean ± S. D.
[0046] Figure 12. Provided technologies can reduce levels of ERG polypeptide. Assessment w as perfonned by western blot quantification of VCaP cells treated with agents at various concentrations.Vehicle was DMSO.
[0047] Figure 13. Provided technologies can reduce levels of ERG polypeptide. Assessment was performed by western blot of VCaP cells treated with agents at various concentrations.
[0048] Figure 14. Reduction of ERG polypeptide levels can be reduced by a proteosome inhibitor. Assessment was performed by western blot of VCaP cells treated with 100 nM agent and / or 5 pM bortezomib.
[0049] Figure 15. Reduction of ERG polypeptide levels can be reduced by a competitive E3 ligand. Assessment was performed by w estern blot of VCaP cells treated with 100 nM agent and / or 1 pM of an E3 ligand.
[0050] Figure 16. Provided technologies can selectively reduce ERG polypeptide levels. Assessment w as performed in VCaP cells. Volcano plot demonstrated no significant off-target protein changes with Agent 3 treatment (N=3). FC: fold-change. N. S.: not significant.
[0051] Figure 17A and Figure 17B. Certain phannacokinetic data in plasma and tumor, respectively. Assessment was performed in VCaP CDX NSG mice. Flelicon is an agent (Agent 3 or Agent 4. as indicated). N=3 mice / timepoint. Data presented as mean ± S. D.
[0052] Figure 18. Provided technologies can reduce levels of ERG polypeptide in vivo. Assessment Page 8 of 6713424615vlAttorney Docket Number: 2012675-0444was performed in VCaP CDX NSG mice using western blot to quantify ERG levels, normalized to vinculin and matched vehicle control. Vehicle was aqueous 10% DMSO, 20% PEG400, 13% PG, 30 mM Tris, final pH ~8. N=3 mice / timepoint. Data presented as mean ± S. D.
[0053] Figure 19. Provided technologies can reduce ERG target gene expression in vivo. Assessment was performed in VCaP CDX NSG mice using qPCRto quantify ARHGD1B expression, normalized to ACTB and vehicle at each timepoint. Vehicle was aqueous 10% DMSO, 20% PEG400, 13% PG, 30 mM Tris, final pH ~8. N=3 mice / timepoint. Data presented as mean ± S. D.
[0054] Figure 20. Provided technologies can inhibit tumor growth in vivo. Assessment was performed in mouse eugonadal VCaP CDX. ***p<0.0001, ***p<0.001, **p<0.01, *p<0.05, N. S. not significant compared to vehicle control using ANOVA (Mixed-effects Model where required). Vehicle was aqueous 10% DMSO, 20% PEG400, 13% PG, 30 mM Tris, final pH ~8. Data presented as mean ± S. D.
[0055] Figure 21. Provided technologies can reduce ERG polypeptide levels in vivo. Assessment was performed by western blot in tumor samples taken from VCaP CDX eugonadal mice. Vehicle was aqueous 10% DMSO, 20% PEG400, 13% PG, 30 mM Tris, final pH ~8.
[0056] Figure 22. Provided technologies can inhibit tumor growth in vivo. Assessment was performed in VCaP CDX hypogonadal mice. ****p<0.0001, ***p<0.001, **p<0.01, *p<0.05, N. S. not significant compared to vehicle control using ANOVA (Mixed-effects Model where required). Vehicle was aqueous 10% DMSO, 20% PEG400, 13% PG, 30 mM Tris, final pH ~8. Data presented as mean ± S. D
[0057] Figure 23. Provided technologies can reduce ERG polypeptide levels in vivo. Assessment was performed by western blot in tumor samples taken from VCaP CDX eugonadal mice. Vehicle was aqueous 10% DMSO, 20% PEG400, 13% PG, 30 mM Tns, final pH ~8.
[0058] Figure 24. Provided technologies can inhibit tumor growth in vivo. Assessment was performed in mCRPC patient-derived xenograft (PDX) eugonadal mice. ***p<0.0001, ***p<0.001, **p<0.01, *p<0.05, N. S. not significant compared to vehicle control using ANOVA (Mixed -effects Model where required). Vehicle was aqueous 10% DMSO, 20% PEG400, 13% PG, 30 mM Tris, final pH ~8. Data presented as mean ± S. D.
[0059] Figure 25. Provided technologies can reduce ERG polypeptide levels in vivo. Assessment was performed by western blot in tumor samples taken from mCRPC PDX eugonadal mice. From left to right: vehicle, q4d, IV; Agent 3, 15 mg / kg, q4d, IV; and Agent 3, 15 mg / kg, q7d, IV. Vehicle was aqueous 10% DMSO, 20% PEG400, 13% PG, 30 mM Tris, final pH ~8.
[0060] Figure 26. Provided technologies can reduce ERG polypeptide levels in vivo. Assessment was performed in mCRPC PDX eugonadal mice using IHC. Top panel and left bar: vehicle, q4d, IV; bottom panel and right bar: Agent 3. 15 mg / kg, q4d. IV. Vehicle was aqueous 10% DMSO. 20% PEG400, 13% PG, 30 mM Tris, final pH ~8.
[0061] Figure 27. Provided technologies can modulate cell cycles. Among other things, provided technologies can reduce S-phase population of cells and provide cell cycle arrest at Go / Gi. Assessment was Page 9 of 6713424615vlAttorney Docket Number: 2012675-0444performed in VCaP cells treated with Agent 3 ± 10 nM DHT for 48 h. For each column, the top section is G2-phase population, the middle section is S-phase population, and the bottom section is Go / Gi -phase population.DETAILED DESCRIPTION OF CERTAIN EMBODIMENTSDefinitions
[0062] As used herein, the following definitions shall apply unless otherwise indicated. For purposes of this disclosure, the chemical elements arc identified in accordance with the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75thEd. Additionally, general principles of organic chemistry are described in “Organic Chemistry”, Thomas Sorrell, University Science Books, Sausalito: 1999, and " March’s Advanced Organic Chemistry”, 5thEd., Ed.: Smith, M. B. and March, J., John Wiley & Sons, New York: 2001.
[0063] Administration: As used herein, the term “administration” typically refers to the administration of a composition to a subject or system. Those of ordinary’ skill in the art will be aware of a variety of routes that may, in appropriate circumstances, be utilized for administration to a subject, for example a human. For example, in some embodiments, administration may be ocular, oral, parenteral, topical, etc. In some particular embodiments, administration may be bronchial (e.g., by bronchial instillation), buccal, dermal (which may be or comprise, for example, one or more of topical to the dermis, intradermal, interdermal, transdermal, etc), enteral, intra-arterial, intradermal, intragastric, intramedullary, intramuscular, intranasal, intraperitoneal, intrathecal, intravenous, intraventricular, within a specific organ (e. g., intrahepatic), mucosal, nasal, oral, rectal, subcutaneous, sublingual, topical, tracheal (e.g., by intratracheal instillation), vaginal, vitreal, etc. In some embodiments, administration may involve dosing that is intermittent (e.g., a plurality of doses separated in time) and / or periodic (e.g., individual doses separated by a common period of time) dosing. In some embodiments, administration may involve continuous dosing (e.g., perfusion) for at least a selected period of time.
[0064] Affinity: As is known in the art, “affinity” is a measure of tire tightness with a particular ligand (e.g., an agent) binds to its partner (e.g., ERG or a portion thereof). Affinities can be measured in different ways. In some embodiments, affinity is measured by a quantitative assay. In some such embodiments, binding partner concentration may be fixed to be in excess of ligand concentration so as to mimic physiological conditions. Alternatively or additionally, in some embodiments, binding partner concentration and / or ligand concentration may be varied. In some such embodiments, affinity may be compared to a reference under comparable conditions (e.g., concentrations).
[0065] Agent: In general, the term “agent”, as used herein, may be used to refer to a compound or entity of any chemical class including, for example, a polypeptide, nucleic acid, saccharide, lipid, small molecule, metal, or combination or complex thereof. In appropriate circumstances, as will be clear from context to those skilled in the art, the term may be utilized to refer to an entity that is or comprises a cell or organism, or Page 10 of 6713424615vlAttorney Docket Number: 2012675-0444a fraction, extract, or component thereof. Alternatively or additionally, as context will make clear, the term may be used to refer to a natural product in that it is found in and / or is obtained from nature. In some instances, again as will be clear from context, the term may be used to refer to one or more entities that is man-made in that it is designed, engineered, and / or produced through action of the hand of man and / or is not found in nature. In some embodiments, an agent may be utilized in isolated or pure form: in some embodiments, an agent may be utilized in crude form. In some embodiments, potential agents may be provided as collections or libraries, for example that may be screened to identify or characterize active agents within them. In some cases, the term “agent” may refer to a compound or entity that is or comprises a polymer; in some cases, the term may refer to a compound or entity that comprises one or more polymeric moieties. In some embodiments, the term “agent” may refer to a compound or entity that is not a polymer and / or is substantially free of any polymer and / or of one or more particular polymeric moieties. In some embodiments, the term may refer to a compound or entity that lacks or is substantially free of any polymeric moiety. In some embodiments, an agent is a compound. In some embodiments, an agent is a stapled peptide.
[0066] Aliphatic. As used herein, “aliphatic” means a straight-chain (i.c., unbranchcd) or branched, substituted or unsubstituted hydrocarbon chain that is completely saturated or that contains one or more units of unsaturation, or a substituted or unsubstituted monocyclic, bicyclic, or polycyclic hydrocarbon ring that is completely saturated or that contains one or more units of unsaturation (but not aromatic), or combinations thereof. In some embodiments, aliphatic groups contain 1-50 aliphatic carbon atoms. In some embodiments, aliphatic groups contain 1-20 aliphatic carbon atoms. In other embodiments, aliphatic groups contain 1-10 aliphatic carbon atoms. In other embodiments, aliphatic groups contain 1-9 aliphatic carbon atoms. In other embodiments, aliphatic groups contain 1-8 aliphatic carbon atoms. In other embodiments, aliphatic groups contain 1-7 aliphatic carbon atoms. In other embodiments, aliphatic groups contain 1-6 aliphatic carbon atoms. In still other embodiments, aliphatic groups contain 1-5 aliphatic carbon atoms, and in yet other embodiments, aliphatic groups contain 1, 2, 3, or 4 aliphatic carbon atoms. Suitable aliphatic groups include, but are not limited to, linear or branched, substituted or unsubstituted alkyl, alkenyl, alkynyl groups and hybrids thereof such as (cycloalkyl)alkyl, (cycloalkenyl)alkyl or (cycloalkyl)alkenyl.
[0067] Alkenyl’. As used herein, the term “alkenyl” refers to an aliphatic group, as defined herein, having one or more double bonds.
[0068] AIM. As used herein, the term “alkyl” is given its ordinary meaning in the art and may include saturated aliphatic groups, including straight-chain alkyl groups, branched-chain alkyl groups, cycloalkyl (alicyclic) groups, alkyl substituted cycloalkyl groups, and cycloalkyl substituted alkyl groups. In some embodiments, alkyl has 1-50 carbon atoms. In certain embodiments, a straight chain or branched chain alkyl has about 1-20 carbon atoms in its backbone (e.g., C1-C20 for straight chain, C2-C20 for branched chain), and alternatively, about 1-10. In some embodiments, cycloalkyl rings have from about 3-10 carbon atoms in their ring structure where such rings are monocyclic, bicyclic, or polycyclic, and alternatively about 5, 6 or 7 carbons in the ring structure. In some embodiments, an alkyl group may be a lower alkyl group, wherein a Page 11 of 6713424615vlAttorney Docket Number: 2012675-0444lower alkyl group comprises 1-4 carbon atoms (e.g., C1-C4 for straight chain lower alkyls).
[0069] Amino acid: In its broadest sense, as used herein, refers to any compound and / or substance that can be incorporated into a polypeptide chain, e.g., through formation of one or more peptide bonds. In some embodiments, an amino acid comprising an amino group and an a carboxylic acid group. In some embodiments, an amino acid has the structure of NH(Ra1)–La1–C(Ra2)(Ra3)–La2–COOH, wherein each variable is independently as described in the present disclosure. In some embodiments, an amino acid has the general structure NH(R’)-C(R’)2-COOH, wherein each R’ is independently as described in the present disclosure. In some embodiments, an amino acid has the general structure H2N-C(R’)2-COOH, wherein R’ is as described in the present disclosure. In some embodiments, an amino acid has the general structure H2N-C(H)(R’)-COOH, wherein R’ is as described in the present disclosure. In some embodiments, an amino acid is a naturally-occurring amino acid. In some embodiments, an amino acid is a non-natural amino acid; in some embodiments, an amino acid is a D-amino acid; in some embodiments, an amino acid is an L-amino acid. ‘ Standard amino acid” refers to any of the twenty standard L-amino acids commonly found in naturally occurring peptides. “Nonstandard amino acid” refers to any amino acid, other than the standard amino acids, regardless of whether it is prepared synthetically or obtained from a natural source. In some embodiments, an amino acid, including a carboxy- and / or amino-tenninal amino acid in a polypeptide, can contain a structural modification as compared with the general structure above. For example, in some embodiments, an amino acid may be modified by methylation, amidation, acetylation, pegylation, glycosylation, phosphorylation, and / or substitution (e.g., of the amino group, tire carboxylic acid group, one or more protons, one or more hydrogens, and / or the hydroxyl group) as compared with the general structure. In some embodiments, such modification may, for example, alter the circulating half-life of a polypeptide containing the modified amino acid as compared with one containing an otherwise identical unmodified amino acid. In some embodiments, such modification does not significantly alter a relevant activity of a polypeptide containing the modified amino acid, as compared with one containing an otherwise identical unmodified amino acid. As will be clear from context, in some embodiments, the term “amino acid” may be used to refer to a free amino acid; in some embodiments it may be used to refer to an amino acid residue of a polypeptide.
[0070] Analog: As used herein, the term “analog” refers to a substance that shares one or more particular structural features, elements, components, or moieties with a reference substance. Typically, an “analog” shows significant structural similarity with the reference substance, for example sharing a core or consensus structure, but also differs in certain discrete ways. In some embodiments, an analog is a substance that can be generated from the reference substance, e.g., by chemical manipulation of the reference substance. In some embodiments, an analog is a substance that can be generated through perfonnance of a synthetic process substantially similar to (e.g., sharing a plurality of steps with) one that generates the reference substance. In some embodiments, an analog is or can be generated through performance of a synthetic process different from that used to generate the reference substance.
[0071] Animal'. As used herein refers to any member of the animal kingdom. In some embodiments, Page 12 of 6713424615vlAttorney Docket Number: 2012675-0444"animal" refers to humans, of either sex and at any stage of development. In some embodiments, "animal" refers to non-human animals, at any stage of development. In certain embodiments, tire non-human animal is a mammal (e.g., a rodent, a mouse, a rat, a rabbit, a monkey, a dog, a cat, a sheep, cattle, a primate, and / or a pig). In some embodiments, animals include, but are not limited to, mammals, birds, reptiles, amphibians, fish, insects, and / or worms. In some embodiments, an animal may be a transgenic animal, genetically engineered animal, and / or a clone.
[0072] Approximately: As used herein, tire term “approximately” or “about,” as applied to one or more values of interest, refers to a value that is similar to a stated reference value. In certain embodiments, the term “approximately” or “about” refers to a range of values that fall within 25%, 20%, 19%. 18%, 17%, 16%, 15%, 14%, 13%. 12%. 11%. 10%. 9%, 8%, 7%, 6%, 5%, 4%, 3%. 2%, 1%, or less in either direction (greater than or less than) of the stated reference value unless otherwise stated or otherwise evident from the context (except where such number would exceed 100% of a possible value).
[0073] Aryk The term “aryl” used alone or as part of a larger moiety as in “aralkyl,” “aralkoxy,” “aryloxyalkyl,” etc. refers to monocyclic, bicyclic or polycyclic ring systems having a total of five to thirty ring members, wherein at least one ring in the system is aromatic. In some embodiments, an aryl group is a monocyclic, bicyclic or polycyclic ring system having a total of five to fourteen ring members, wherein at least one ring in the system is aromatic, and wherein each ring in the system contains 3 to 7 ring members. In some embodiments, an aryl group is a biaryl group. The term “aryl” may be used interchangeably with the term “aryl ring.” In certain embodiments of the present disclosure, “aryl” refers to an aromatic ring system which includes, but not limited to, phenyl, biphenyl, naphthyl, binaphthyl, anthracyl and the like, which may bear one or more substituents. In some embodiments, also included within the scope of the term “aryl,” as it is used herein, is a group in which an aromatic ring is fused to one or more non-aromatic rings, such as indanyl, phthalimidyl, naphthimidyl, phenanthridinyl, or tetrahydronaphthyl, and the like, where a radical or point of attachment is on an aryl ring.
[0074] Associated with: Two events or entities are “associated” with one another, as that term is used herein, if the presence, level and / or form of one is correlated with that of the other. For example, a particular entity (e.g., nucleic acid (e.g, genomic DNA, transcripts, mRNA, etc.), polypeptide, genetic signature, metabolite, microbe, etc..) is considered to be associated with a particular disease, disorder, or condition, if its presence, level and / or form correlates with incidence of and / or susceptibility to the disease, disorder, or condition (e.g., across a relevant population).
[0075] Binding-. It will be understood that the term “binding”, as used herein, typically refers to a non-covalent association between or among agents. In many embodiments herein, binding is addressed with respect to particular agents and ERG. It will be appreciated by those of ordinary skill in the art that such binding may be assessed in any of a variety of contexts. In some embodiments, binding is assessed with respect to ERG. In some embodiments, binding is assessed with respect to one or more amino acid residues of ERG. In some embodiments, binding is assessed with respect to one or more amino acid residues Page 13 of 6713424615vlAttorney Docket Number: 2012675-0444corresponding to (e.g., similarly positioned in three dimensional space and / or having certain similar properties and / or functions) those of ERG.
[0076] Binding site'. The term “binding site”, as used herein, refers to a region of a target polypeptide, formed in three-dimensional space, that includes one or more or all interaction residues of the target polypeptide. In some embodiments, “binding site” may refer to one or more amino acid residues which comprise or are one or more or all interaction amino acid residues of a target polypeptide. As will be understood by those of ordinary skill in the art, a binding site may include residues that are adjacent to one another on a linear chain, and / or that arc distal to one another on a linear chain but near to one another in three-dimensional space when a target polypeptide is folded. A binding site may comprise amino acid residues and / or saccharide residues.
[0077] Carrier: as used herein, refers to a diluent, adjuvant, excipient, or vehicle with which a composition is administered. In some exemplary embodiments, carriers can include sterile liquids, such as, for example, water and oils, including oils of petroleum, animal, vegetable or synthetic origin, such as, for example, peanut oil, soybean oil, mineral oil, sesame oil and the like. In some embodiments, carriers are or include one or more solid components.
[0078] Comparable: As used herein, the term “comparable” refers to two or more agents, entities, situations, sets of conditions, etc., that may not be identical to one another but that are sufficiently similar to permit comparison there between so that one skilled in the art will appreciate that conclusions may reasonably be drawn based on differences or similarities observed. In some embodiments, comparable sets of conditions, circumstances, individuals, or populations are characterized by a plurality of substantially identical features and one or a small number of varied features. Those of ordinary skill in the art will understand, in context, what degree of identity is required in any given circumstance for two or more such agents, entities, situations, sets of conditions, etc. to be considered comparable. For example, those of ordinary skill in the art will appreciate that sets of circumstances, individuals, or populations are comparable to one another when characterized by a sufficient number and type of substantially identical features to warrant a reasonable conclusion that differences in results obtained or phenomena observed under or with different sets of circumstances, individuals, or populations are caused by or indicative of the variation in those features that are varied.
[0079] Cycloaliphatic. The term “cycloaliphatic,” as used herein, refers to saturated or partially unsaturated aliphatic monocyclic, bicyclic, or polycyclic ring systems having, e.g., from 3 to 30, members, wherein the aliphatic ring system is optionally substituted. Cycloaliphatic groups include, without limitation, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, cycloheptenyl, cyclooctyl, cyclooctenyl, norbomyl, adamantyl, and cyclooctadienyl. In some embodiments, the cycloalkyl has 3-6 carbons. The terms “cycloaliphatic” may also include aliphatic rings that are fused to one or more aromatic or nonaromatic rings, such as decahydronaphthyl or tetrahydronaphthyl, where a radical or point of attachment is on an aliphatic ring. In some embodiments, a carbocyclic group is bicyclic. In some Page 14 of 6713424615vlAttorney Docket Number: 2012675-0444embodiments, a carbocyclic group is tricyclic. In some embodiments, a carbocyclic group is polycyclic. In some embodiments, “cycloaliphatic” (or “carbocycle” or “cycloalkyl”) refers to a monocyclic C3-C10, or C3-Ce hydrocarbon, or a C4-C10, or Cs-Cio bicyclic hydrocarbon that is completely saturated or that contains one or more units of unsaturation, but which is not aromatic, or a C9-C16 tricyclic hydrocarbon that is completely saturated or that contains one or more units of unsaturation, but which is not aromatic.
[0080] Derivative: As used herein, the term “derivative” refers to a structural analogue of a reference substance. That is, a “derivative” is a substance that shows significant structural similarity with the reference substance, for example sharing a core or consensus structure, but also differs in certain discrete ways. In some embodiments, a derivative is a substance that can be generated from the reference substance by chemical manipulation. In some embodiments, a derivative is a substance that can be generated through performance of a synthetic process substantially similar to (e.g., sharing a plurality of steps with) one that generates the reference substance.
[0081] Halogerr. The term “halogen” means F, Cl, Br, or I.
[0082] Heteroaliphatic. The term “hctcroaliphatic” is given its ordinary’ meaning in the art and refers to aliphatic groups as described herein in which one or more carbon atoms are replaced with one or more heteroatoms (e.g., oxygen, nitrogen, sulfur, silicon, phosphorus, and the like).
[0083] Heteroalkyl'. The term “heteroalkyl” is given its ordinary meaning in the art and refers to alkyl groups as described herein in which one or more carbon atoms is replaced with a heteroatom (e.g., oxygen, nitrogen, sulfur, silicon, phosphorus, and the like). Examples of heteroalkyl groups include, but are not limited to, alkoxy, polyethylene glycol)-, alkyl-substituted amino, tetrahydrofuranyl, piperidinyl, morpholinyl, etc.
[0084] Heteroaryl'. The terms “heteroaryl” and “heteroar-,” used alone or as part of a larger moiety, e.g.. “heteroaralkyl,” or “heteroaralkoxy,” refer to monocyclic, bicyclic or polycyclic ring systems having, for example, a total of five to thirty, e.g., 5, 6, 9, 10, 14, etc., ring members, wherein at least one ring in the system is aromatic and at least one aromatic ring atom is a heteroatom. In some embodiments, a heteroatom is nitrogen, oxygen or sulfur. In some embodiments, a heteroaryl group is a group having 5 to 10 ring atoms (z. e., monocyclic, bicyclic or polycyclic), in some embodiments 5, 6, 9, or 10 ring atoms. In some embodiments, a heteroaryl group has 6, 10, or 14 zr electrons shared in a cyclic array; and having, in addition to carbon atoms, from one to five heteroatoms. Heteroaryl groups include, without limitation, thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolizinyl, purinyl, naphthyridinyl, and pteridinyl. In some embodiments, a heteroaryl is a heterobiaryl group, such as bipyridyl and the like. The terms “heteroaryl” and “heteroar-”, as used herein, also include groups in which a heteroaromatic ring is fused to one or more aryl, cycloaliphatic, or heterocyclyl rings, where a radical or point of attachment is on a heteroaromatic ring. Non-limiting examples include indolyl, isoindolyl, benzothienyl, benzofuranyl, dibenzofuranyl, indazolyl, benzimidazolyl, benzthiazolyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl.Page 15 of 6713424615vlAttorney Docket Number: 2012675-0444quinazolinyl, quinoxalinyl, 4H-quinolizinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, and pyrido[2,3-b]-l,4-oxazin-3(4H)-one. A heteroaryl group may be monocyclic, bicyclic or polycyclic. The term ‘‘heteroaryl” may be used interchangeably with tire tenns “heteroaryl ring.” “heteroaryl group,” or “heteroaromatic,” any of which tenns include rings that are optionally substituted. Tire term “heteroaralkyl” refers to an alkyl group substituted by a heteroaryl group, wherein the alkyl and heteroaryl portions independently are optionally substituted.
[0085] Heteroatom'. The term “heteroatom” means an atom that is not carbon and is not hydrogen. In some embodiments, a heteroatom is oxygen, sulfur, nitrogen, phosphorus, boron or silicon (including any- oxidized form of nitrogen, sulfur, phosphorus, or silicon; the quatemized form of any basic nitrogen or a substitutable nitrogen of a heterocyclic ring (for example, N as in 3,4-dihydro-277-pyrrolyl), NH (as in pyrrolidinyl) or NR+(as in N-substituted pyrrolidinyl); etc.). In some embodiments, a heteroatom is boron, nitrogen, oxygen, silicon, sulfur, or phosphorus. In some embodiments, a heteroatom is nitrogen, oxygen, silicon, sulfur, or phosphorus. In some embodiments, a heteroatom is nitrogen, oxygen, sulfur, or phosphorus. In some embodiments, a hctcroatom is nitrogen, oxygen or sulfur.
[0086] Heterocyclyl As used herein, the tenns “heterocycle,” “heterocyclyl,” “heterocyclic radical,” and “heterocyclic ring” are used interchangeably and refer to a monocyclic, bicyclic or polycyclic ring moiety (e.g., 3-30 membered) that is saturated or partially unsaturated and has one or more heteroatom ring atoms. In some embodiments, a heteroatom is boron, nitrogen, oxygen, silicon, sulfur, or phosphorus. In some embodiments, a heteroatom is nitrogen, oxygen, silicon, sulfur, or phosphorus. In some embodiments, a heteroatom is nitrogen, oxygen, sulfur, or phosphorus. In some embodiments, a heteroatom is nitrogen, oxygen or sulfur. In some embodiments, a heterocyclyl group is a stable 5- to 7-membered monocyclic or 7- to 10-membered bicyclic heterocyclic moiety that is either saturated or partially unsaturated, and having, in addition to carbon atoms, one or more, preferably one to four, heteroatoms, as defined above. When used in reference to a ring atom of a heterocycle, the term "nitrogen" includes substituted nitrogen. As an example, in a saturated or partially unsaturated ring having 0-3 heteroatoms selected from oxygen, sulfur or nitrogen, the nitrogen may be N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl), or+NR (as in N-substituted pyrrolidinyl). A heterocyclic ring can be attached to its pendant group at any heteroatom or carbon atom that results in a stable structure and any of the ring atoms can be optionally substituted. Examples of such saturated or partially unsaturated heterocyclic radicals include, without limitation, tetrahydrofuranyl, tetrahydrothienyl, pyrrolidinyl, piperidinyl, pyrrolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, oxazolidinyl, piperazinyl, dioxanyl, dioxolanyl, diazepinyl, oxazepinyl, thiazepinyl, morpholinyl, and quinuclidinyl. The terms “heterocycle,” “heterocyclyl,” “heterocyclyl ring,” “heterocyclic group,” “heterocyclic moiety,” and “heterocyclic radical,” are used interchangeably herein, and also include groups in which a heterocyclyl ring is fused to one or more aryl, heteroaryl, or cycloaliphatic rings, such as indolinyl, 3H-indolyl, chromanyl, phenanthridinyl, or tetrahydroquinolinyl, where a radical or point of attachment is on a heteroaliphatic ring. A heterocyclyl group may be monocyclic, bicyclic or polycyclic. The Page 16 of 6713424615vlAttorney Docket Number: 2012675-0444term “heterocyclylalkyl” refers to an alkyl group substituted by a heterocyclyl, wherein the alkyl and heterocyclyl portions independently are optionally substituted.
[0087] Homology: As used herein, the term “homology” refers to the overall relatedness between polymeric molecules, e.g., between nucleic acid molecules (e.g.. DNA molecules and / or RNA molecules) and / or between polypeptide molecules. In some embodiments, polymeric molecules are considered to be “homologous” to one another if their sequences are at least 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% identical. In some embodiments, polymeric molecules are considered to be “homologous” to one another if their sequences arc at least 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%. 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% similar (e.g., containing residues with related chemical properties at corresponding positions). For example, as is well known by those of ordinary skill in the art, certain amino acids are typically classified as similar to one another as "hydrophobic” or “hydrophilic” amino acids, and / or as having “polar” or “non-polar” side chains. Substitution of one amino acid for another of the same type may often be considered a “homologous” substitution. Typical amino acid categorizations arc summarized below (hydrophobicity scale of Kyle and Doolittle, 1982: A simple method for displaying the hydropathic character of a protein. J. Mol. Biol. 157: 105-132):3 Letter 1 Letter Side Chain Side Chain Hydropathy Index of Amino AcidCode Code Polarity Acidity' / Basicity Kyte and Doolittle Alanine Ala A nonpolar neutral 1.8 Arginine Arg R polar basic -4.5 Asparagine Asn N polar neutral -3.5 Aspartic acid Asp D polar acidic -3.5 Cysteine Cys C nonpolar neutral 2.5 Glutamic acid Glu E polar acidic -3.5 Glutamine Gin Q polar neutral -3.5 Glycine Gly G nonpolar neutral -0.4 Histidine His H polar basic -3.2 Isoleucine Ile I nonpolar neutral 4.5 Leucine Leu L nonpolar neutral 3.8 Lysine Lys K polar basic -3.9 Methionine Met M nonpolar neutral 1.9 Phenylalanine Phe F nonpolar neutral 2.8Proline Pro P nonpolar neutral -1.6 Serine Ser S polar neutral -0.8 Threonine Thr T polar neutral -0.7 Tryptophan Trp W nonpolar neutral -0.9 Tyrosine Tyr Y polar neutral -1.3Valine Val V nonpolar neutral 4.2Ambiguous Amino Acids 3 -Letter 1 -Letter Asparagine or aspartic acid Asx B Glutamine or glutamic acid Glx Z Leucine or Isoleucine Xie JUnspecified or unknown amino acid Xaa XPage 17 of 6713424615vlAttorney Docket Number: 2012675-0444
[0088] As will be understood by those skilled in the art, a variety of algorithms are available that permit comparison of sequences in order to determine their degree of homology, including by permitting gaps of designated length in one sequence relative to another when considering which residues “correspond"’ to one another in different sequences. Calculation of the percent homology between two nucleic acid sequences, for example, can be performed by aligning the two sequences for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second nucleic acid sequences for optimal alignment and non-corresponding sequences can be disregarded for comparison purposes). In certain embodiments, the length of a sequence aligned for comparison purposes is at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%. at least 90%, at least 95%, or substantially 100% of the length of the reference sequence. The nucleotides at corresponding nucleotide positions are then compared. When a position in the first sequence is occupied by the same nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position; when a position in the first sequence is occupied by a similar nucleotide as the corresponding position in the second sequence, then the molecules are similar at that position. The percent homology between the two sequences is a function of the number of identical and similar positions shared by tire sequences, taking into account the number of gaps, and the length of each gap, which needs to be introduced for optimal alignment of the two sequences. Representative algorithms and computer programs useful in determining the percent homology between two nucleotide sequences include, for example, tire algorithm of Meyers and Miller (CABIOS, 1989, 4: 11-17), which has been incorporated into the ALIGN program (version 2.0) using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4. The percent homology between two nucleotide sequences can, alternatively, be determined for example using the GAP program in the GCG software package using an NWSgapdna.CMP matrix.
[0089] Partially unsaturated'. As used herein, the term “partially unsaturated” refers to a moiety that includes at least one double or triple bond. The term “partially unsaturated” is intended to encompass groups having multiple sites of unsaturation, but is not intended to include aryl or heteroaryl moieties.
[0090] Peptide: The term “peptide” as used herein refers to a polypeptide. In some embodiments, a peptide is a polypeptide that is relatively short, for example having a length of less than about 100 amino acids, less than about 50 amino acids, less than about 40 amino acids less than about 30 amino acids, less than about 25 amino acids, less than about 20 amino acids, less than about 15 amino acids, or less than 10 amino acids. In some embodiments, a length is about 5-20, 5-19, 5-18, 5-17, 5-16, 5-15, 10-20, 10-19, 10-18, 10-17, 10-16, 10-15, 11-20, 11-19, 11-18, 11-17, 11-16, 11-15, 12-20, 12-19, 12-18, 12-17, 12-16, 12-15, 13-20, 13-19, 13-18, 13-17, 13-16, 13-15, 14-20, 14-19, 14-18, 14-17, 14-16, 14-15, or about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12. 13, 14, 15, 16, 17, 18, 19, or 20 amino acids.
[0091] Pharmaceutical composition: As used herein, the term “pharmaceutical composition” refers to an active agent, formulated together with one or more pharmaceutically acceptable carriers. In some embodiments, active agent is present in unit dose amount appropriate for administration in a therapeutic Page 18 of 6713424615vlAttorney Docket Number: 2012675-0444regimen that shows a statistically significant probability of achieving a predetermined therapeutic effect when administered to a relevant population. In some embodiments, pharmaceutical compositions may be specially fonnulated for administration in solid or liquid form, including those adapted for the following: oral administration, for example, drenches (aqueous or non-aqueous solutions or suspensions), tablets, e.g., those targeted for buccal, sublingual, and systemic absorption, boluses, powders, granules, pastes for application to the tongue: parenteral administration, for example, by subcutaneous, intramuscular, intravenous or epidural injection as, for example, a sterile solution or suspension, or sustained-release formulation; topical application, for example, as a cream, ointment, or a controlled-release patch or spray applied to the skin, lungs, or oral cavity; intravaginally or intrarectally, for example, as a pessary, cream, or foam; sublingually; ocularly: transdermally; or nasally, pulmonary, and to other mucosal surfaces.
[0092] Pharmaceutically acceptable: As used herein, the phrase “pharmaceutically acceptable” refers to those compounds, materials, compositions, and / or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit / risk ratio.
[0093] Pharmaceutically acceptable carrier: As used herein, the term “pharmaceutically acceptable carrier” means a pharmaceutically -acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, or solvent encapsulating material, involved in carrying or transporting the subject compound from one organ, or portion of the body, to another organ, or portion of the body. Each carrier must be “acceptable” in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient. Some examples of materials which can serve as pharmaceutically-acceptable carriers include: sugars, such as lactose, glucose and sucrose; starches, such as com starch and potato starch; cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients, such as cocoa butter and suppository waxes: oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, com oil and soybean oil; glycols, such as propylene glycol; polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffering agents, such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water: isotonic saline: RingeR’s solution; ethyl alcohol: pH buffered solutions; polyesters, polycarbonates and / or polyanhydrides; and other non-toxic compatible substances employed in pharmaceutical formulations.
[0094] Pharmaceutically acceptable salt: The term “pharmaceutically acceptable salt”, as used herein, refers to salts of such compounds that are appropriate for use in pharmaceutical contexts, i.e., salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit / risk ratio. Pharmaceutically acceptable salts are well known. For example, S. M. Berge, et al. describes pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 66: 1-19 (1977). In Page 19 of 6713424615vlAttorney Docket Number: 2012675-0444some embodiments, pharmaceutically acceptable salts include, but are not limited to, nontoxic acid addition salts, which are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other known methods such as ion exchange. In some embodiments, pharmaceutically acceptable salts include, but are not limited to, adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate. 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate. 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, / i-toluenesulfonate, undecanoate, valerate salts, and the like. In some embodiments, pharmaceutically acceptable salts include, but are not limited to, nontoxic base addition salts, such as those formed by acidic groups of provided compounds with bases. Representative alkali or alkaline earth metal salts include salts of sodium, lithium, potassium, calcium, magnesium, and the like. In some embodiments, pharmaceutically acceptable salts are ammonium salts (e.g., -N(R)3+). In some embodiments, pharmaceutically acceptable salts are sodium salts. In some embodiments, pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, alkyl having from 1 to 6 carbon atoms, sulfonate and aryl sulfonate.
[0095] Polypeptide: As used herein refers to any polymeric chain of amino acids. In some embodiments, a polypeptide has an amino acid sequence that occurs in nature. In some embodiments, a polypeptide has an amino acid sequence that does not occur in nature. In some embodiments, a polypeptide has an amino acid sequence that is engineered in that it is designed and / or produced through action of the hand of man. In some embodiments, a polypeptide may comprise or consist of natural amino acids, nonnatural amino acids, or both. In some embodiments, a polypeptide may comprise or consist of only natural amino acids or only non-natural amino acids. In some embodiments, a polypeptide may comprise D-amino acids, L-amino acids, or both. In some embodiments, a polypeptide may comprise only D-amino acids. In some embodiments, a polypeptide may comprise only L-amino acids. In some embodiments, a polypeptide may include one or more pendant groups or other modifications, e.g., modifying or attached to one or more amino acid side chains, at the polypeptide’s N-tenninus, at the polypeptide’s C-terminus, or any combination thereof. In some embodiments, such pendant groups or modifications may be selected from tire group consisting of acetylation, amidation, lipidation, methylation, pegylation, etc., including combinations thereof. In some embodiments, a polypeptide may be cyclic, and / or may comprise a cyclic portion. In some embodiments, a polypeptide is not cyclic and / or does not comprise any cyclic portion. In some embodiments, a polypeptide is linear. In some embodiments, a polypeptide may be or comprise a stapled polypeptide. In Page 20 of 6713424615vlAttorney Docket Number: 2012675-0444some embodiments, the term “polypeptide” may be appended to a name of a reference polypeptide, activity, or structure; in such instances it is used herein to refer to polypeptides that share the relevant activity or structure and thus can be considered to be members of the same class or family of polypeptides. For each such class, the present specification provides and / or those skilled in the art will be aware of exemplary polypeptides within the class whose amino acid sequences and / or functions are known; in some embodiments, such exemplary polypeptides are reference polypeptides for the polypeptide class or family. In some embodiments, a member of a polypeptide class or family shows significant sequence homology or identity with, shares a common sequence motif (e.g., a characteristic sequence element) with, and / or shares a common activity (in some embodiments at a comparable level or within a designated range) with a reference polypeptide of the class; in some embodiments with all polypeptides within the class). For example, in some embodiments, a member polypeptide shows an overall degree of sequence homology or identity with a reference polypeptide that is at least about 30-40%, and is often greater than about 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more and / or includes at least one region (e.g., a conserved region that may in some embodiments be or comprise a characteristic sequence element) that shows very high sequence identity, often greater than 90% or even 95%, 96%, 97%, 98%, or 99%. Such a conserved region usually encompasses at least 3-4 and often up to 20 or more amino acids; in some embodiments, a conserved region encompasses at least one stretch of at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or more contiguous amino acids. In some embodiments, a relevant polypeptide may comprise or consist of a fragment of a parent polypeptide. In some embodiments, a useful polypeptide as may comprise or consist of a plurality of fragments, each of which is found in the same parent poly peptide in a different spatial arrangement relative to one another than is found in the polypeptide of interest (e.g., fragments that are directly linked in the parent may be spatially separated in the polypeptide of interest or vice versa, and / or fragments may be present in a different order in the polypeptide of interest than in the parent), so that the polypeptide of interest is a derivative of its parent polypeptide.
[0096] Protecting group-. The term “protecting group,” as used herein, is well known in the art and includes those described in detail in Protecting Groups in Organic Synthesis, T. W. Greene and P. G. M. Wuts, 3rdedition, John Wiley & Sons, 1999, the entirety of which is incorporated herein by reference. Also included are those protecting groups specially adapted for nucleoside and nucleotide chemistry described in Current Protocols in Nucleic Acid Chemistry, edited by Serge L. Beaucage et al. 06 / 2012, the entirety of Chapter 2 is incorporated herein by reference. Suitable amino-protecting groups include methyl carbamate, ethyl carbamate, 9-fluorenylmethyl carbamate (Fmoc), 9-(2-sulfo)fluorenylmethyl carbamate, 9-(2,7-dibromo)fluorenylmethyl carbamate, 2,7-di-t-butyl-[9-( 10,10-dioxo- 10,10,10,10— tetrahydrothioxanthyl)]methyl carbamate (DBD-Tmoc). 4-methoxyphenacyl carbamate (Phenoc), 2,2,2-trichloroethyl carbamate (Troc), 2-trimethylsilylethyl carbamate (Teoc), 2-phenylethyl carbamate (hZ). 1-(l-adamantyl)-l-methylethyl carbamate (Adpoc), l,l-dimethyl-2-haloethyl carbamate, l,l-dimethyl-2,2-dibromoethyl carbamate (DB-t-BOC), l,l-dimethyl-2,2,2-trichloroethyl carbamate (TCBOC), 1-methyl-l- Page 21 of 6713424615vlAttorney Docket Number: 2012675-0444(4-biphenylyl)ethyl carbamate (Bpoc), l-(3,5-di-t-butylphenyl)-l-methylethyl carbamate (t-Bumeoc), 2-(2‘- and 4’-pyridyl)ethyl carbamate (Pyoc), 2-(N, N-dicyclohexylcarboxamido)ethyl carbamate, t-butyl carbamate (BOC), 1-adamantyl carbamate (Adoc), vinyl carbamate (Voc), allyl carbamate (Alloc), 1-isopropylallyl carbamate (Ipaoc), cinnamyl carbamate (Coc), 4-nitrocinnamyl carbamate (Noc). 8-quinolyl carbamate, N-hydroxypiperidinyl carbamate, alkyldithio carbamate, benzyl carbamate (Cbz), p-methoxybenzyl carbamate (Moz), p-nitrobenzyl carbamate, p-bromobenzyl carbamate, p-chlorobenzyl carbamate, 2,4-dichlorobenzyl carbamate, 4-methylsulfinylbenzyl carbamate (Msz), 9-anthrylmethyl carbamate, diphenylmethyl carbamate, 2-methylthioethyl carbamate, 2-methylsulfonylethyl carbamate, 2-(p-toluenesulfonyl)ethyl carbamate, [2-(1,3-dithianyl)]methyl carbamate (Dmoc), 4-methylthiophenyl carbamate (Mtpc). 2,4-dimethylthiophenyl carbamate (Bmpc), 2-phosphonioethyl carbamate (Peoc), 2-triphenylphosphonioisopropyl carbamate (Ppoc), l,l-dimethyl-2-cyanoethyl carbamate, m-chloro-p-acyloxybenzyl carbamate, p-(dihydroxyboryl)benzyl carbamate, 5-benzisoxazolylmethyl carbamate, 2-(trifluoromethyl)-6-chromonylmethyl carbamate (Tcroc), m-nitrophenyl carbamate, 3,5-dimethoxybenzyl carbamate, o-nitrobenzyl carbamate, 3,4-dimethoxy-6-nitrobenzyl carbamate, phenyl(o-nitrophenyl)methyl carbamate, phenothiazinyl-(10)-carbonyl derivative, N'-p-toluenesulfonylaminocarbonyl derivative, N’-phenylaminothiocarbonyl derivative, t-amyl carbamate, S-benzyl thiocarbamate, p-cyanobenzyl carbamate, cyclobutyl carbamate, cyclohexyl carbamate, cyclopentyl carbamate, cyclopropylmethyl carbamate, p-decyloxybenzyl carbamate, 2,2-dimethoxycarbonylvinyl carbamate, o-(N, N-dimethylcarboxamido)benzyl carbamate, l,l-dimethyl-3-(N, N-dimethylcarboxamido)propyl carbamate, 1, 1-dimethylpropynyl carbamate, di(2-pyridyl)methyl carbamate, 2-furanylmethyl carbamate, 2-iodoethyl carbamate, isoborynl carbamate, isobutyl carbamate, isonicotinyl carbamate, p-(p’-methoxyphenylazo)benzyl carbamate, 1-methylcyclobutyl carbamate, 1 -methylcyclohexyl carbamate, 1 -methyl- 1 -cyclopropylmethyl carbamate, 1-methyl-l-(3,5-dimethoxyphenyl)ethyl carbamate, l-methyl-l-(p-phenylazophenyl)ethyl carbamate, 1-methyl-1 -phenylethyl carbamate, l-methyl-l-(4-pyridyl)ethyl carbamate, phenyl carbamate, p-(phenylazo)benzyl carbamate, 2,4,6-tri-t-butylphenyl carbamate, 4-(trimethylammonium)benzyl carbamate, 2,4,6-trimethylbenzyl carbamate, formamide, acetamide, chloroacetamide, trichloroacetamide, trifluoroacetamide, phenylacetamide, 3-phenylpropanamide, picolinamide, 3-pyridylcarboxamide, N-benzoylphenylalanyl derivative, benzamide, p-phenylbenzamide, o-nitophenylacetamide. o-nitrophenoxyacetamide, acetoacetamide, (N’-dithiobenzyloxycarbonylamino)acetamide, 3-(p-hydroxyphenyl)propanamide, 3-(o-nitrophenyl)propanamide, 2-methyl-2-(o-nitrophenoxy)propanamide, 2-methyl-2-(o-phenylazophenoxy)propanamide, 4-chlorobutanamide, 3-methyl-3-nitrobutanamide, o-nitrocinnamide, N-acetylmethionine derivative, o-nitrobenzamide, o-(benzoyloxymethyl)benzamide, 4,5-diphenyl-3-oxazolin-2-one, N-phthalimide, N-dithiasuccinimide (Dts), N-2,3-diphenylmaleimide, N-2,5-dimethylpyrrole. N-l.l,4,4-tetramethyldisilylazacyclopentane adduct (STABASE). 5-substituted 1,3-dimethyl- 1,3,5-triazacyclohexan-2-one, 5-substituted 1,3-dibenzyl- 1,3,5-triazacyclohexan-2-one, 1-substituted 3,5-dinitro-4-pyridone, N-methylamine, N-allylamine, N-[2- Page 22 of 6713424615vlAttorney Docket Number: 2012675-0444(trimethylsilyl)ethoxy]methylamine (SEM), N-3-acetoxypropylamine, N-(1-isopropyl-4-nitro-2-oxo-3-pyrrolin-3-yl)amine, quaternary ammonium salts, N-benzylamine, N-di(4-methoxyphenyl)methylamine, N-5-dibenzosuberylamine, N-triphenylmethylamine (Tr), N-[(4-methoxyphenyl)diphenylmethyl]amine (MMTr), N-9-phenylfluorenylamine (PhF), N-2,7-dichloro-9-fluorenylmethyleneamine, N-ferrocenylmethylamino (Fem), N-2-picolylamino N ’-oxide, N-l,l-dimethylthiomethyleneamine, N-benzylideneamine, N-p-methoxybenzylideneamine, N-diphenylmethyleneamine, N-[(2-pyridyl)mesityl]methyleneamine, N-(N’, N’-dimethylaminomethylene)amine, N, N’-isopropylidenediamine, N-p-nitrobenzylideneamine, N-salicylideneamine, N-5-chlorosalicylideneamine, N-(5-chloro-2-hydroxyphenyl)phenylmethyleneamine, N-cyclohexylideneamine, N-(5,5-dimethyl-3-oxo-l-cyclohexenyl)amine, N-borane derivative. N-diphenylborinic acid derivative. N-[phenyl(pentacarbonylchromium- or tungsten)carbonyl]amine, N-copper chelate, N-zinc chelate, N-nitroamine, N-nitrosoamine, amine N-oxide, diphenylphosphinamide (Dpp), dimethylthiophosphinamide (Mpt), diphenylthiophosphinamide (Ppt), dialkyl phosphoramidates, dibenzyl phosphoramidate, diphenyl phosphoramidate, benzenesulfenamide, o-nitrobenzenesulfenamide (Nps), 2,4-dinitrobenzenesulfenamide, pentachlorobenzenesulfenamide, 2-nitro-4-methoxybenzenesulfenamide, triphenylmethylsulfenamide, 3-nitropyridinesulfenamide (Npys), p-toluenesulfonamide (Ts), benzenesulfonamide, 2.3,6,-trimethyl-4-methoxybenzenesulfonamide (Mtr), 2,4,6-trimethoxybenzenesulfonamide (Mtb), 2,6-dimethyl-4-methoxybenzenesulfonamide (Pme), 2,3,5,6-tetramethyl-4-methoxybenzenesulfonamide (Mte), 4-methoxybenzenesulfonamide (Mbs), 2,4,6-trimethylbenzenesulfonamide (Mts), 2,6-dimethoxy-4-methylbenzenesulfonamide (iMds), 2,2,5,7,8-pentamethylchroman-6-sulfonamide (Pmc),methanesulfonamide (Ms), β-trimethylsilylethanesulfonamide (SES), 9-anthracenesulfonamide, 4-(4’,8’-dimethoxynaphthylmethyl)benzenesulfonamide (DNMBS), benzylsulfonamide, trifluoromethylsulfonamide, and phenacylsulfonamide.
[0097] In some embodiments, suitable mono-protected amines include, but are not limited to, aralkylamines, carbamates, allyl amines, amides, and the like. Examples of suitable mono-protected amino moieties include t-butyloxy carbonylamino (-NHBOC), ethyloxycarbonylamino, methyloxycarbonylamino, trichloroethyloxycarbonylamino, allyloxycarbonylamino (-NHAlloc), benzyloxocarbonylamino (-NHCBZ), allylamino, benzylamino (-NHBn), fluorenylmethylcarbonyl (-NHFmoc). formamido, acetamido, chloroacetamido, dichloroacetamido, trichloroacetamido, phenylacetamido, trifluoroacetamido, benzamido, t-butyldiphenylsilyl, and the like. In some embodiments, suitable di-protected amines include amines that are substituted with two substituents independently selected from those described above as mono-protected amines, and further include cyclic imides, such as phthalimide, maleimide, succinimide, and the like. In some embodiments, suitable di-protected amines include pyrroles and the like, 2,2,5,5-tetramethyl-[1.2.5]azadisilolidine and the like, and azide.
[0098] Suitably protected carboxylic acids further include, but are not limited to, silyl-, alkyl-, alkenyl-, aryl, and arylalkyl-protected carboxylic acids. Examples of suitable silyl groups include trimethylsilyl, Page 23 of 6713424615vlAttorney Docket Number: 2012675-0444triethylsilyl, t-butyldimethylsilyl, t-butyldiphenyl silyl, triisopropylsilyl, and the like. Examples of suitable alkyl groups include methyl, benzyl, p-methoxybenzyl, 3,4-dimethoxybenzyl, trityl, t-butyl, tetrahydropyran-2-yl. Examples of suitable alkenyl groups include allyl. Examples of suitable aryl groups include optionally substituted phenyl, biphenyl, or naphthyl. Examples of suitable arylalkyl groups include optionally substituted benzyl (e.g., p-methoxybenzyl (MPM), 3,4-dimethoxybenzyl, O-nitrobenzyl, p-nitrobenzyl, p-halobenzyl, 2,6-dichlorobenzyl, p-cyanobenzyl), and 2- and 4-picolyl. In some embodiments, suitable protected carboxylic acids include, but are not limited to, optionally substituted Ci-e aliphatic esters, optionally substituted aryl esters, silyl esters, activated esters, amides, hydrazides, and the like. Examples of such ester groups include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, benzyl, and phenyl ester, wherein each group is optionally substituted. Additional suitable protected carboxylic acids include oxazolines and ortho esters.
[0099] Suitable hydroxyl protecting groups include methyl, methoxylmethyl (MOM), methylthiomethyl (MTM), t-butylthiomethyl, (phenyldimethylsilyl)methoxymethyl (SMOM), benzyloxymethyl (BOM), p-methoxybenzyloxymethyl (PMBM), (4-methoxyphenoxy)methyl (p-AOM), guaiacolmethyl (GUM), t-butoxymethyl, 4-pentenyloxymethyl (POM), siloxymethyl, 2-methoxyethoxymethyl (MEM), 2,2,2-trichloroethoxymethyl, bis(2-chloroethoxy)methyl, 2-(trimethylsilyl)ethoxymethyl (SEMOR), tetrahydropyranyl (THP), 3-bromotetrahydropyranyl, tetrahydrothiopyranyl, 1-methoxycyclohexyl, 4-methoxytetrahydropyranyl (MTHP), 4-methoxytetrahydrothiopyranyl, 4-methoxytetrahydrothiopyranyl S, S-dioxide, l-[(2-chloro-4-methyl)phenyl]-4-methoxypiperidin-4-yl (CTMP), l,4-dioxan-2-yl, tetrahydrofuranyl, tetrahydrothiofuranyl, 2,3,3a,4,5,6,7,7a-octahydro-7,8,8-trimethyl-4,7-methanobenzofuran-2-yl, 1-ethoxyethyl, l-(2-chloroethoxy)ethyl, 1 -methyl- 1-methoxy ethyl, 1-methyl-l-benzyloxyethyl, l-methyl-l-benzyloxy-2-fluoroethyl, 2.2,2-trichloroethyl, 2-trimethylsilylethyl, 2-(phenylselenyl)ethyl, t-butyl, allyl, p-chlorophenyl, p-methoxyphenyl, 2,4-dinitrophenyl, benzyl, p-methoxybenzyl, 3,4-dimethoxybenzyl, o-nitrobenzyl, p-nitrobenzyl, p-halobenzyl, 2,6-dichlorobenzyl, p-cyanobenzyl, p-phenylbenzyl, 2-picolyl, 4-picolyl, 3-methyl-2-picolyl N-oxido, diphenylmethyl, p,p’-dinitrobenzhydryl, 5-dibenzosuberyl, triphenylmethyl, a-naphthyldiphenylmethyl, p-methoxyphenyldiphenylmethyl, di(p-methoxyphenyl)phenylmethyl, tri(p-methoxyphenyl)methyl, 4-(4 ’-bromophenacyloxyphenyl)diphenylmethyl, 4, 4 ’.4’ '-tris(4.5-dichlorophthalimidophenyl)methyl, 4, 4 ’.4’ '-tris(levulinoyloxyphenyl)methyL 4,4’,4”-tris(benzoyloxyphenyl)methyl, 3-(imidazol-l-yl)bis(4’,4”-dimethoxyphenyl)methyl, 1, 1-bis(4-m ethoxyphenyl)-! ’-pyrenylmethyl, 9-anthryl, 9-(9-phenyl)xanthenyl, 9-(9-phenyl-10-oxo)anthryl, l,3-benzodithiolan-2-yl, benzisothiazolyl S, S-dioxido, trimethylsilyl (TMS), triethylsilyl (TES), triisopropylsilyl (TIPS), dimethylisopropylsilyl (IPDMS), diethylisopropylsilyl (DEIPS), dimethylthexylsilyl, t-butyldimethylsilyl (TBDMS). t-butyldiphenylsilyl (TBDPS), tribenzylsilyl, tri-p-xylylsilyl, triphenylsilyl, diphenylmethylsilyl (DPMS), t-butylmethoxyphenylsilyl (TBMPS), formate, benzoylformate, acetate, chloroacetate, dichloroacetate, trichloroacetate, trifluoroacetate, methoxy acetate, triphenylmethoxyacetate, phenoxyacetate, p-chlorophenoxyacetate, 3-phenylpropionate, 4-oxopentanoate Page 24 of 6713424615vlAttorney Docket Number: 2012675-0444(levulinate), 4,4-(ethylenedithio)pentanoate (levulinoyldithioacetal), pivaloate, adamantoate, crotonate, 4-methoxycrotonate, benzoate, p-phenylbenzoate, 2,4,6-trimethylbenzoate (mesitoate), alkyl methyl carbonate, 9-fluorenylmethyl carbonate (Fmoc), alkyl ethyl carbonate, alkyl 2,2,2-trichloroethyl carbonate (Troc), 2-(trimethylsilyl)ethyl carbonate (TMSEC), 2-(phenylsulfonyl) ethyl carbonate (Psec), 2-(triphenylphosphonio) ethyl carbonate (Peoc), alkyl isobutyl carbonate, alkyl vinyl carbonate alkyl allyl carbonate, alkyl p-nitrophenyl carbonate, alkyl benzyl carbonate, alkyl p-m ethoxybenzyl carbonate, alkyl 3,4-dimethoxybenzyl carbonate, alkyl o-nitrobenzyl carbonate, alkyl p-nitrobenzyl carbonate, alkyl S-benzyl thiocarbonate, 4-ethoxy-1-naphthyl carbonate, methyl dithiocarbonate, 2-iodobenzoate, 4-azidobutyrate, 4-nitro-4-methylpentanoate, o-(dibromomethyl)benzoate, 2-formylbenzenesulfonate, 2-(methylthiomethoxy)ethyl, 4-(methylthiomethoxy)butyrate, 2-(methylthiomethoxymethyl)benzoate, 2,6-dichloro-4-methylphenoxyacetate, 2,6-dichloro-4-( 1, 1,3,3-tetramethylbutyl)phenoxyacetate, 2,4— bis( 1,1-dimethylpropyl)phenoxyacetate, chlorodiphenylacetate, isobutyrate, monosuccinoate, (E)-2-methyl-2-butenoate, o-(methoxycarbonyl)benzoate, a-naphthoate, nitrate, alkyl N, N, N’, N’-tctramcthylphosphorodiamidatc, alkyl N-phcnylcarbamatc, borate, dimcthylphosphinothioyl, alkyl 2,4-dinitrophenylsulfenate, sulfate, methanesulfonate (mesylate), benzylsulfonate, and tosylate (Ts). For protecting 1.2- or 1,3— diols, the protecting groups include methylene acetal, ethylidene acetal, 1-t-butylethylidene ketal, 1-phenylethylidene ketal, (4-methoxyphenyl)ethylidene acetal, 2,2,2-trichloroethylidene acetal, acetonide, cyclopentylidene ketal, cyclohexylidene ketal, cycloheptylidene ketal, benzylidene acetal, p-methoxybenzylidene acetal, 2,4-dimethoxybenzylidene ketal, 3,4-dimethoxybenzylidene acetal, 2-nitrobenzylidene acetal, methoxymethylene acetal, ethoxymethylene acetal, dimethoxymethylene ortho ester, 1 -methoxy ethylidene ortho ester, 1-ethoxyethylidene ortho ester, 1,2— dimethoxyethylidene ortho ester, a-methoxybenzylidene ortho ester, l-(N, N-dimethylamino)ethylidene derivative, a-(N, N’-dimethylamino)benzylidene derivative, 2-oxacyclopentylidene ortho ester, di— t— butylsilylene group (DTBS), l,3-(l,l,3,3-tetraisopropyldisiloxanylidene) derivative (TIPDS), tetra-t-butoxydisiloxane-l,3-diylidene derivative (TBDS), cyclic carbonates, cyclic boronates, ethyl boronate, and phenyl boronate.
[0100] In some embodiments, a hydroxyl protecting group is acetyl, t-butyl, t-butoxymethyl, methoxymethyl, tetrahydropyranyl, 1 -ethoxyethyl, 1 -(2-chloroethoxy)ethyl, 2- trimethylsilylethyl, p-chlorophenyl, 2,4-dinitrophenyl, benzyl, benzoyl, p-phenylbenzoyl, 2,6- dichlorobenzyl, diphenylmethyl, p-nitrobenzyl, triphenylmethyl (trityl), 4,4'-dimethoxytrityl, trimethylsilyl, triethylsilyl, t-butyldimethylsilyl, t-butyldiphenylsilyl, triphenylsilyl, triisopropylsilyl, benzoylformate, chloroacetyl, trichloroacetyl, trifluoroacetyl, pivaloyl, 9- fluorenylmethyl carbonate, mesylate, tosylate, triflate, trityl, monomethoxytrityl (MMTr), 4,4'-dimethoxytrityl, (DMTr) and 4,4',4"-trimethoxytrityl (TMTr), 2 -cyanoethyl (CE or Cne), 2-(trimethylsilyl)ethyl (TSE), 2-(2-nitrophenyl)ethyl, 2-(4-cyanophenyl)ethyl, 2-(4-nitrophenyl)ethyl (NPE). 2-(4-nitrophenylsulfonyl)ethyl, 3, 5 -dichlorophenyl, 2,4-dimethylphenyl, 2-nitrophenyl, 4-nitrophenyl, 2,4,6-trimethylphenyl, 2-(2-nitrophenyl)ethyl, butylthiocarbonyl, 4,4',4"-tris(benzoyloxy)trityl, diphenylcarbamoyl,Page 25 of 6713424615vlAttorney Docket Number: 2012675-0444levulinyl, 2-(dibromomethyl)benzoyl (Dbmb), 2-(isopropylthiomethoxymethyl)benzoyl (Ptmt), 9-phenylxanthen-9-yl (pixyl) or 9-(p-methoxyphenyl)xanthine-9-yl (MOX). In some embodiments, each of the hydroxyl protecting groups is, independently selected from acetyl, benzyl, t- butyldimethylsilyl, t-butyldiphenylsilyl and 4,4'-dimethoxytrityl. In some embodiments, the hydroxyl protecting group is selected from the group consisting of trityl, monomethoxytrityl and 4,4'-dimethoxytrityl group. In some embodiments, a phosphorous linkage protecting group is a group attached to the phosphorous linkage (e.g., an intemucleotidic linkage) throughout oligonucleotide synthesis. In some embodiments, a protecting group is attached to a sulfur atom of a phosphorothioate group. In some embodiments, a protecting group is attached to an oxygen atom of an intemucleotide phosphorothioate linkage. In some embodiments, a protecting group is attached to an oxygen atom of the intemucleotide phosphate linkage. In some embodiments a protecting group is 2 -cyanoethyl (CE or Cne), 2-trimethylsilylethyl, 2 -nitroethyl, 2-sulfonylethyl, methyl, benzyl, o-nitrobenzyl, 2-(p-nitrophenyl)ethyl (NPE orNpe), 2-phenylethyl, 3 -(N-tert-butylcarboxamido)-l -propyl, 4-oxopentyl, 4-methylthio-l -butyl, 2 -cyano- 1,1 -dimethylethyl, 4-N-methylaminobutyl, 3-(2-pyridyl)-1-propyl, 2-[N-methyl-N-(2-pyridyl)]aminoethyl, 2-(N-formyl, N-methyl)aminoethyl, or 4-[N-methyl-N-(2,2,2-trifluoroacetyl)amino]butyl.
[0101] Protected thiols are well known in the art and include those described in detail in Greene (1999). Suitable protected thiols further include, but are not limited to, disulfides, thioethers, silyl thioethers, thioesters, thiocarbonates, and thiocarbamates, and the like. Examples of such groups include, but are not limited to, alkyl thioethers, benzyl and substituted benzyl thioethers, triphenylmethyl thioethers, and trichloroethoxycarbonyl thioester, to name but a few.
[0102] Reference: As used herein describes a standard or control relative to which a comparison is performed. For example, in some embodiments, an agent, animal, individual, population, sample, sequence or value of interest is compared with a reference or control agent, animal, individual, population, sample, sequence or value. In some embodiments, a reference or control is tested and / or determined substantially simultaneously with the testing or determination of interest. In some embodiments, a reference or control is a historical reference or control, optionally embodied in a tangible medium. Typically, as would be understood by those skilled in the art, a reference or control is determined or characterized under comparable conditions or circumstances to those under assessment. Those skilled in the art will appreciate when sufficient similarities are present to justify reliance on and / or comparison to a particular possible reference or control.
[0103] Specificity-. As is known in the art, ‘’specificity” is a measure of the ability of a particular ligand (e.g., an agent) to distinguish its binding partner (e.g., ERG) from other potential binding partners (e.g., another protein, another portion (e g., domain) of ERG.
[0104] Substitution-. As described herein, compounds of the disclosure may contain optionally substituted and / or substituted moieties. In general, the term “substituted,” whether preceded by the term “optionally” or not, means that one or more hydrogens of the designated moiety are replaced with a suitable substituent. Unless otherwise indicated, an “optionally substituted” group may have a suitable substituent at Page 26 of 6713424615vlAttorney Docket Number: 2012675-0444each substitutable position of the group, and when more than one position in any given structure may be substituted with more than one substituent selected from a specified group, the substituent may be either tire same or different at every position. Combinations of substituents envisioned by this disclosure are preferably those that result in the formation of stable or chemically feasible compounds. Hie term “stable,” as used herein, refers to compounds that are not substantially altered when subjected to conditions to allow for their production, detection, and, in certain embodiments, their recovery, purification, and use for one or more of the purposes disclosed herein. In some embodiments, example substituents are described below.
[0105] Suitable monovalent substituents are halogen; -(CH2)0-4R°: -(CH2)0-4OR°; -O(CH2)0-4R°, -O-(CH2)0-4C(O)OR°; -(CH2)0-4CH(OR°) -(CH2)0-4Ph. which may be substituted with R°; -(CH2)0-4O(CH2)0-1Ph which may be substituted with R°; -CH=CHPh, which may be substituted with R°; -(CH2)0-4O(CH2)0-1-pyridyl which may be substituted with R°; -NO2; -CN; -N3; -(CH2)0-4N(R°)2; -(CH2)0-4N(R°)C(O)R°; -N(R°)C(S)R°; -(CH2)0-4N(R°)C(O)N(R°)2; -N(R°)C(S)N(R°)2; -(CH2)0-4N(R°)C(O)OR°; -N(R°)N(R°)C(O)R°; -N(R°)N(R°)C(O)N(R°)2; -N(R°)N(R°)C(O)OR°; -(CH2)0-4C(O)R°; -C(S)R°; -(CH2)0-4C(O)OR°; -(CH2)0-4C(O)SR°; -(CH2)0-4C(O)OSi(R°)3; -(CH2)0-4OC(O)R°: -OC(0)(CH2)o^SR°, -SC(S)SR°; -(CH2)0-4SC(O)R°; -(CH2)0-4C(O)N(R°)2; -C(S)N(R°)2; -C(S)SR°; -SC(S)SR°, -(CH2)0-4OC(O)N(R°)2; -C(O)N(OR°)R°; -C(O)C(O)R°; -C(O)CH2C(O)R°; -C(NOR°)R°; -(CH2)0-4SSR°: -(CH2)0-4S(O)2R°; -(CH2)0-4S(O)2OR°: -(CH2)0-4OS(O)2R°: -S(O)2N(R°)2; -(CH2)0-4S(O)R°; -N(R°)S(O)2N(R°)2; -N(R°)S(O)2R°; -N(0R°)R°; -C(NH)N(R°)2; -Si(R°)3; -OSi(R°)3; P(R°)2; P(OR°)2; OP(R°)2;-OP(OR°)2; -N(RO)P(R°)2; -B(RO)2; -OB(R°)2: -P(O)(RO)2; -OP(O)(R°)2; -N(R°)P(O)(R°)2; -(C1-4straight or branched alkylene)O-N(R°)2; or -(C1-4straight or branched alkylene)C(O)O-N(R°)2; wherein each R° may be substituted as defined below7and is independently hydrogen, C1-10(e.g., C1-8, C1-6, C1-4, etc.) aliphatic, C1-10(e.g., C1-5, C1-10, C1-6, C1-4, etc.) heteroaliphatic having 1-5 heteroatoms independently selected from nitrogen, oxygen, sulfur, silicon and phosphorus, -CH2-(C6-10(e.g., C6, C10, etc.) aryl), -O(CH2)0-1(C5-10(e.g., C6, C10, etc.) aryl). -CH2-(5-10 (e.g., 5-9, 5-6, 5. 6, 9, 10, etc.) membered heteroaryl ring), a 3-10 (e.g., 3-, 3, 4, 5, 6, 7, 8, 9, 10, etc.) membered, monocyclic, bicyclic, or polycyclic, saturated, partially unsaturated or aryl ring having 0-5 heteroatoms independently selected from nitrogen, oxygen, sulfur, silicon and phosphorus, or, notwithstanding the definition above, two independent occurrences of R°, taken together with their intervening atom(s), form a 3-10 (e.g., 5-10, 3, 4, 5, 6, 7. 8, 9, 10, etc.) membered, monocyclic, bicyclic, or polycyclic, saturated, partially unsaturated or aryl ring having 0-5 heteroatoms independently selected from nitrogen, oxygen, sulfur, silicon and phosphorus, which may be substituted as defined below.
[0106] Suitable monovalent substituents on R° (or the ring formed by taking two independent occurrences of R° together with their intervening atoms), are independently halogen, -(CH2)0-2R*. -(haloR*), -(CH2)0-2OH, -(CH2)0-2OR*, -(CH2)0-2CH(OR*)2; -O(haloR’), -CN, -N3, -(CH2)0-2C(O)R*, -(CH2)o2C(O)OH, -(CH2)0-2C(O)OR*, -(CH2)0-2SR*, -(CH2)0-2SH, -(CH2)0-2NH2, -(CH2)0-2NHR*, -(CH2)0-2NR*2,Page 27 of 6713424615vlAttorney Docket Number: 2012675-0444-NO2, -SiR*3, -OSiR’s, -C(O)SR* - (Ci- straight or branched alkylene)C(O)OR*, or -SSR* wherein each R* is unsubstituted or where preceded by “halo” is substituted only with one or more halogens, and is independently selected from C1-4aliphatic, -CH2PI1, -0(CH2)o-iPh, or a 3-6 (e.g., 3-5, 5-6, etc.)-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. Suitable divalent substituents on a saturated carbon atom of R° include =0 and =S.
[0107] Suitable divalent substituents are the following: =0, =S, =NNR*, =NNHC(0)R*, =NNHC(0)0R*, =NNHS(O)2R*, =NR*, =N0R*, -O(C(R*2))2-3O-, or -S(C(R*2))2-3S-, wherein each independent occurrence of R* is selected from hydrogen, C1-6 aliphatic which may be substituted as defined below, or an unsubstituted 3-6 (e.g.. 3-5, 5-6, etc.)-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. Suitable divalent substituents that are bound to vicinal substitutable carbons of an “optionally substituted” group include: -O(CR*2)2-3O-, wherein each independent occurrence of R is selected from hydrogen, C1-6 aliphatic which may be substituted as defined below, or an unsubstituted 3-6 (e.g., 3-5, 5-6, etc.)-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. Suitable trivalent substituents are =CR* wherein R* is as described herein and =N.
[0108] Suitable substituents on the aliphatic group of R* are halogen, -R*, -(haloR*), -OH, -OR*, -O(haloR’), -CN, -C(O)OH, -C(O)OR*, -NH2, -NHR*, -NR*2, or -NO2, wherein each R* is unsubstituted or where preceded by “halo” is substituted only with one or more halogens, and is independently Ci 4 aliphatic, -CH2Ph, -O(CH2)0-1Ph, or a 3-6 (e.g., 3-5, 5-6, etc.)-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
[0109] In some embodiments, suitable substituents on a substitutable nitrogen are -R\ -NR’2. -C(O)Rt, -C(O)OR1, -C(O)C(O)R1, -C(O)CH2C(O)R', -S(O)2R', -S(O)2NRt2, -C(S)NR'2, -C(NH)NR'2, or -N(Rt)S(O)2Rt; wherein each R' is independently hydrogen, Ci 6 aliphatic which may be substituted as defined below, unsubstituted -OPh, or an unsubstituted 3-6 (e.g., 3-5, 5-6, etc.)-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or, notwithstanding the definition above, two independent occurrences of R'. taken together with their intervening atom(s) form an unsubstituted 3-12 (e.g., 3-10, 3-6, 3. 4, 5, 6, 7. 8, 9, 10, etc.) membered saturated, partially unsaturated, or aryl mono- or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
[0110] Suitable substituents on the aliphatic group of R ' are independently halogen, -R*, -(haloR*), -OH, -OR*, -O(haloR*), -CN, -C(O)OH, -C(O)OR*, -NH2, -NHR*, -NR*2, or-NO2, wherein each R* is unsubstituted or where preceded by “halo” is substituted only with one or more halogens, and is independently C1-4aliphatic, -CH2Ph, -O(CH2)0-1Ph, or a 3-6 (e.g., 3-5. 5-6, etc.)-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
[0111] Subject: As used herein, the term “subject” or “test subject” refers to any organism to which a Page 28 of 6713424615vlAttorney Docket Number: 2012675-0444provided compound or composition is administered in accordance with the present disclosure e.g., for experimental, diagnostic, prophylactic, and / or therapeutic purposes. Typical subjects include animals (e.g., mammals such as mice, rats, rabbits, non-human primates, and humans; insects; worms; etc.) and plants. In some embodiments, a subject may be suffering from, and / or susceptible to a disease, disorder, and / or condition. In some embodiments, a subject is a human.
[0112] Susceptible to: An individual who is ‘'susceptible to” a disease, disorder, and / or condition is one who has a higher risk of developing the disease, disorder, and / or condition than does a member of the general public. In some embodiments, an individual who is susceptible to a disease, disorder and / or condition may not have been diagnosed with the disease, disorder, and / or condition. In some embodiments, an individual who is susceptible to a disease, disorder, and / or condition may exhibit symptoms of the disease, disorder, and / or condition. In some embodiments, an individual who is susceptible to a disease, disorder, and / or condition may not exhibit symptoms of the disease, disorder, and / or condition. In some embodiments, an individual who is susceptible to a disease, disorder, and / or condition will develop the disease, disorder, and / or condition. In some embodiments, an individual who is susceptible to a disease, disorder, and / or condition will not develop the disease, disorder, and / or condition.
[0113] Target polypeptide: A “target polypeptide”, as that term is used herein, is a polypeptide with which an agent interacts. In some embodiments, a target polypeptide is a ERG polypeptide. In some embodiments, a target polypeptide comprises, consists essentially of, or is a binding site of ERG polypeptide.
[0114] Therapeutic agent: As used herein, the phrase “therapeutic agent” refers to an agent that, when administered to a subject, has a therapeutic effect and / or elicits a desired biological and / or phannacological effect. In some embodiments, a therapeutic agent is any substance that can be used to alleviate, ameliorate, relieve, inhibit, prevent, delay onset of, reduce severity of. and / or reduce incidence of one or more symptoms or features of a disease, disorder, and / or condition.
[0115] Treat: As used herein, the term “treat,” “treatment,” or '‘treating” refers to any method used to partially or completely alleviate, ameliorate, relieve, inhibit, prevent, delay onset of, reduce severity of, and / or reduce incidence of one or more symptoms or features of a disease, disorder, and / or condition.Treatment may be administered to a subject who does not exhibit signs of a disease, disorder, and / or condition. In some embodiments, treatment may be administered to a subject who exhibits only early signs of the disease, disorder, and / or condition, for example for the purpose of decreasing the risk of developing pathology associated with the disease, disorder, and / or condition.
[0116] Unsaturated: The term “unsaturated” as used herein, means that a moiety has one or more units of unsaturation.
[0117] Unless otherwise specified, salts, such as pharmaceutically acceptable acid or base addition salts, stereoisomeric forms, and tautomeric forms, of provided compound are included.
[0118] As used herein in the present disclosure, unless otherwise clear from context, (i) the term “a” or “an” may be understood to mean “at least one”; (ii) the term “or” may be understood to mean “and / or”; (iii)Page 29 of 6713424615vlAttorney Docket Number: 2012675-0444the terms “comprising”, “comprise”, “including” (whether used with “not limited to” or not), and “include” (whether used with “not limited to” or not) may be understood to encompass itemized components or steps whether presented by themselves or together with one or more additional components or steps; (iv) the term “another” may be understood to mean at least an additional / second one or more: (v) the terms “about” and “approximately” may be understood to permit standard variation as would be understood by those of ordinary skill in the art; and (vi) where ranges are provided, endpoints are included.Certain Agents
[0119] In some embodiments, the present disclosure provides various agents. In some embodiments, the present disclosure provides an agent, wherein the agent has the structure of:TBM-L°-LBM,or a salt thereof, wherein:TBM is a target binding agent that can bind ERG;L° is a linker, or covalent bond or an optionally substituted, bivalent C1-C30 aliphatic or heteroaliphatic group having 1-12 heteroatoms, wherein one or more methylene units of the group are each optionally and independently replaced with -C(R’)2- -Cy-, -O-, -S-, -S-S-, -N(R’)-, -C(O)-, -C(S)--C(NR’)-, -C(0)N(R’)-, -N(R’)C(O)N(R’)-, -N(R’)C(O)O- -S(O)-, -S(O)2-, -S(O)2N(R’)-, -C(O)S--C(O)O-, -(OCH2CH2)n-, or an amino acid residue:n is 1-20;LBM is an E3 ligase binding moiety;each -Cy- is independently an optionally substituted bivalent 3-30 membered ring having 0-10 heteroatoms;each R’ is independently -R, -C(O)R, -CO2R, or -SO2R; andeach R is independently -H, or an optionally substituted group selected from C1-30 aliphatic, C1-30 heteroaliphatic having 1-10 heteroatoms, C6-30aryl, C6-30aryaliphatic. C6-30arylheteroaliphatic having 1-10 heteroatoms, 5-30 membered heteroaryl having 1-10 heteroatoms, and 3-30 membered heterocyclyl having 1- 10 heteroatoms; ortwo R groups are optionally and independently taken together to form a covalent bond; or two or more R groups on the same atom are optionally and independently taken together with the atom to form an optionally substituted, 3-30 membered ring having, in addition to the atom, 0-10 heteroatoms; ortwo or more R groups on two or more atoms are optionally and independently taken together with their intervening atom(s) to form an optionally substituted, 3-30 membered ring having, in addition to the intervening atom(s). 0-10 heteroatoms.
[0120] In some embodiments, an agent comprises a target binding moiety, a linker, and an E3 ligase binding moiety. In some embodiments, a target binding moiety is or comprises a stapled peptide moiety. In Page 30 of 6713424615vlAttorney Docket Number: 2012675-0444some embodiments, a target binding moiety can bind to ERG. In some embodiments, a target binding moiety is -[PTBM], wherein PTBMis or comprises a peptide. In some embodiments, a target binding moiety is –[PTBM], wherein PTBMis or comprises a stapled peptide. In some embodiments, pTBMcan bind ERG.
[0121] In some embodiments, an agent can provide different properties and / or activities compared to a reference agent. In some embodiments, an agent can provide improved properties and / or activities compared to a reference agent. In some embodiments, a reference agent is an otherwise identical agent but without linker and / or E3 ligase binding moiety. In some embodiments, a reference agent has the structure of TBM-L°-H or a salt thereof. In some embodiments, a reference agent has the structure of TBM-H or a salt thereof. In some embodiments, a target binding moiety in an agent is -[PTBM], In some embodiments, a reference agent is PTBM. In some embodiments, a reference agent is [PTBM]-L°-H.
[0122] In some embodiments, LBM is an E3 ligase binding moiety. In some embodiments, LBM can bind an E3 ligase. In some embodiments, in a reference agent LBM cannot bind an E3 ligase that an agent can bind.
[0123] Various embodiments of agents, target binding moictics, linkers, E3 ligase binding moictics, TBM, L°, LBM and methods thereof are described herein as examples.Target Binding Moieties
[0124] In some embodiments, provided technologies comprise target binding moieties that can bind ERG. For example, in various agent having the structure of TBM-L°-LBM, TBM is a target binding moiety. Among other things, target binding moieties can bind target agents, e.g., an ERG polypeptide, and can promote delivery of agents comprising target binding moieties to targets that comprise or express target agents that target binding moieties can bind. In some embodiments, a target binding moiety can bind to a target agent which is or comprise a polypeptide. In some embodiments, a target binding moiety can bind to a target agent which is or comprise an ERG polypeptide.
[0125] In some embodiments, a target binding moiety is or comprises | P|. In some embodiments, a target binding moiety is -[PTBM], In some embodiments, PTBMis or comprises a peptide. In some embodiments, PTBMis a peptide. In some embodiments, PTBMis or comprise a stapled peptide. In some embodiments, PTBMis a stapled peptide. In some embodiments, PTBMis or comprises a stitched peptide. In some embodiments, PTBMis a stitched peptide. In some embodiments, PTBMcomprises a N-terminus group and / or C -terminus group as described herein. Certain embodiments of peptides, including stapled peptides, are described herein as examples.Peptides
[0126] In some embodiments, a provided agent is or comprises a peptide. In some embodiments, a provided agent is a peptide. In some embodiments, PTBMis a peptide. In some embodiments, a peptide is a stapled peptide. In some embodiments, a provided agent is a stapled peptide. In some embodiments, PTBMis Page 31 of 6713424615vlAttorney Docket Number: 2012675-0444a stapled peptide. Stapled peptides as described herein are typically peptides in which two or more amino acids of a peptide chain are linked through connection of two peptide backbone atoms of the amino acid residues and, as is understood by those skilled in the art, the connection is not through the peptide backbone between the linked amino acid residues. In some embodiments, a staple as described herein is a linker that link one amino acid residue to another amino acid residue, e.g., through bonding to a peptide backbone atom of each of the amino acid residues and, as is understood by those skilled in the art, the connection through a staple is not through the peptide backbone between the linked amino acid residues. In some embodiments, a staple bonds to the peptide backbone by replacing one or more hydrogen and / or substituents (e.g., side chains, 0, S, etc.) on peptide backbone atoms (e.g., C, N, etc.). In some embodiments, side chains form portions of staples. In some embodiments, a staple is bonded to two carbon backbone atoms, e.g.. two alpha carbon atoms. In some embodiments, a staple comprises C(R’)2 orN(R’), either individually or as part of a large moiety, wherein R’ is R and is taken together with another group attached to a backbone atom which can be R (e.g., Ra3) and their intervening atoms to form a ring as described herein (e.g., when PyrS2 is stapled in various peptides).
[0127] In some embodiments, a stapled peptide comprises one or more staples. In some embodiments, a stapled peptide comprises tw o or more staples. In some embodiments, a stapled peptide comprises three or more staples. In some embodiments, a stapled peptide comprises four or more staples. In some embodiments, there are three staples in a stapled peptide. In some embodiments, there are four staples in a stapled peptide.
[0128] As will be appreciated by those of ordinary’ skill in the art, a variety of peptide stapling technologies are available, including both hydrocarbon-stapling and non-hydrocarbon-stapling technologies, and can be utilized in accordance with the present disclosure. Various technologies for stapled and stitched peptides, including various staples and / or methods for manufacturing are available and may be utilized in accordance with the present disclosure, e.g., those described in WO 2019 / 051327 and WO 2020 / 041270, the staples of each of which are incorporated herein by reference.
[0129] In some embodiments, a peptide, e.g., a stapled peptide, is or comprise a helical structure. In some embodiments, a peptide is a stapled peptide.
[0130] In some embodiments, peptides, e.g., staple peptides, of the present disclosure is or comprises a helix structure.
[0131] In some embodiments, provided stereochemistry at staple -backbone connection points and / or combinations thereof, optionally together with one or more structural elements of provided peptide, e.g., staple chemistry (hydrocarbon, non-hydrocarbon), staple length, etc. can provide various benefits, such as improved preparation yield, purity, and / or selectivity, improved properties e.g., improved solubility, improved stability, lowered toxicity, improved selectivity, etc.), improved activities, etc. In some embodiments, provided stereochemistry and / or stereochemistry combinations are different from those typically used, e.g., those of US 9617309, US 2015-0225471, US 2016-0024153, US 2016-0215036, US Page 32 of 6713424615vlAttorney Docket Number: 2012675-04442016-0244494, WO 2017 / 062518, and provided one or more of benefits described in the present disclosure.
[0132] In some embodiments, a peptide, e.g., PTBM, is or comprises a peptide comprising:X1X2X3X4X5X6X7X8X9X1°,wherein:each of X1, X2, X3, X4, X5, X6, X7, X8, X9, and X10is independently an amino acid residue.
[0133] In some embodiments, a peptide, e.g., PTBM, is or comprises a peptide comprising:X1X2X3X4X5X6X7X8X9X10X11X12X13X14,wherein:each of X1, X2, X3, X4, X5. X6. X7. X8, X9, X10, X11, X12, X13, and X14is independently an amino acid residue.
[0134] In some embodiments, a peptide, e.g., PTBM, is or comprises a peptide comprising:[X]pX1X2X3X4X5X6X7X8X9X10[X11]pl l[X12]pl2[X13]pl3[X14]pl4[X15]pl5[X16]pl6[X17]pl7[X18]pl8[X]p-, wherein:each of pl 1. pl2, pl3. pl4, p 15. pl6, pl7 and p 18 is independently 0 or 1;each of p and p’ is independently 0-10;each of X, X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12, X13, X14, X15, X16, X17and X18is independently an amino acid residue.
[0135] In some embodiments, a peptide, e.g., PTBM, is or comprisesRN–[X]pX1X2X3X4X5X6X7X8X9X10[X11]p11[X12]p12[X13]p13[X14]p14[X15]p15[X16]p16[X17]p17[X18]p18[X]p-Rc, wherein each variable is independently as described herein.
[0136] In some embodiments, a peptide, e.g., PTBM, is or comprises X1X2X3X4X5X6X7X8X9Xlc’[X11]pii[X12]pi2[X13]pi3[X14]pi4[X15]pi5[X16]pi6[X17]pi7[X18]pi8[X19]pi9[X2O]p2o[X21]p21[ X22]P22[X23]P23, wherein each of p 11, p!2, p!3, p!4, p!5, p!6, p!7, p!8, p!9, p20, p21, p22, and p23 is independently 0 or 1, and each of X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, Xn, X12, X13, X14, X15, X16, X17, X18, X19, X20. X21, X22, and X23is independently an amino acid residue as described herein.
[0137] In some embodiments, p is 0-10. In some embodiments, p is 0. In some embodiments, p is 1. In some embodiments, p is 2. In some embodiments, p is 3. In some embodiments, p is 4. In some embodiments, p is 5.. In some embodiments, p is 6. In some embodiments, p is 7. In some embodiments, p is 8. In some embodiments, p is 9. In some embodiments, p is 10. In some embodiments, p’ is 0-10. In some embodiments, p' is 0. In some embodiments, p’ is 1. In some embodiments, p’ is 2. In some embodiments, p’ is 3. In some embodiments, p' is 4. In some embodiments, p' is 5. In some embodiments, p’ is 6. In some embodiments, p’ is 7. In some embodiments, p’ is 8. In some embodiments, p’ is 9. In some embodiments, p’ is 10.
[0138] In some embodiments, pl 1 is 0. In some embodiments, pH is 1. In some embodiments, p!2 is 0. In some embodiments, p!2 is 1. In some embodiments, p!2 is 0. In some embodiments, p!2 is 1. In some embodiments, p 13 is 0. In some embodiments, p!3 is 1. In some embodiments, p!4 is 0. In some embodiments, p 14 is 1. In some embodiments, p 15 is 0. In some embodiments. p!5 is 1. In somePage 33 of 6713424615vlAttorney Docket Number: 2012675-0444embodiments, p!6 is 0. In some embodiments, p!6 is 1. In some embodiments, p!7 is 0. In some embodiments, p 17 is 1. In some embodiments, p 18 is 0. In some embodiments, pl 8 is 1.
[0139] In some embodiments, a peptide is stapled. In some embodiments, two X (e.g., two of X1, X2, X3, X4, X5. X6. X7. X8, X9, X10, X11, X12, X13, X14, X15, X16, X17, X18, X19, X20, X21, X22, and X23) are stapled.
[0140] In some embodiments, one or more of amino acid residues (e.g., X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12, X13, X14, X15, X16, X17, X18, X19, X20, X21, X22, X23, etc.) is independently a D-amino acid residue. In some embodiments, each of X1, X2, X3, X4, X5, X6, X7, X8, X9, and X10is independently a D-amino acid residue. In some embodiments, each of X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12, X13, and X14is independently a D-amino acid residue. In some embodiments, each of X, X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12, X13, X14, X15, X16, X17and X18is independently a D-amino acid residue. In some embodiments, each of X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12, X13, X14, X15, X16, X17, X18, X19, X20, X21, X22, and X23is independently a D-amino acid residue.
[0141] In some embodiments, a peptide, e.g., PTBM, has the structure of formula I:RN–[X]pX1X2X3X4X5X6X7X8X9X10[X11]p11[X12]p12[X13]p13[X14]p14[X15]p15[X16]p16[X17]p17[X18]p18[X]p'–Rc,I
[0142] In some embodiments, RNis an N-terminus capping group. In some embodiments, RNis -C(O)R. wherein R is as described herein. In some embodiments, R is -H. In some embodiments, R is optionally substituted Ci-e aliphatic. In some embodiments, R is optionally substituted Cue alkyl. In some embodiments, R is methyl.
[0143] In some embodiments, Rcis a C-terminus capping group. In some embodiments, Rccomprises a PEG moiety. In some embodiments, Rcis -O-LRC-R’ wherein each of LRCand R’ is independently as described herein. In some embodiments, Rcis -OR’, wherein R’ is optionally substituted Ci-Cw aliphatic. In some embodiments, Rcis -OR’, wherein R’ is optionally substituted Ci-Cio alkyl. In some embodiments, Rcis -OR’, wherein R’ is optionally substituted C1-30 heteroaliphatic having 1-10 heteroatoms. In some embodiments, R(is -LR<-R’, wherein one or more methylene unit of LRCare replaced with -O- and R’ is as described herein. In some embodiments, Rcis -O-LRC-R’, wherein LRCis optionally substituted Cue alkylene and R’ is as described herein. In some embodiments. Rcis -O-LRC-R’, wherein LRCis optionally substituted Ci-6 alkylene and R’ is an optionally substituted group selected from Ce-so aryl and 5-30 membered heteroaryl having 1-10 heteroatoms. In some embodiments, Rcis -OR’ wherein R’ is optionally substituted Ce-jo aryl aliphatic. In some embodiments, Rcis -N(R’)2wherein each R’ is independently as described herein. In some embodiments, Rcis -NHR’ wherein R’ is as described herein. In some embodiments, Rcis –N(R)2wherein each R is independently as described herein. In some embodiments, Rcis -NHR wherein R is as described herein. In some embodiments, R is -H. In some embodiments, R is optionally substituted Ci-6 aliphatic. In some embodiments, R is optionally substituted Ci-6 alkyl. In some embodiments, R is methyl. In some embodiments, R is ethyl. In some embodiments, Rcis -NH2. In some embodiments, Rcis -NHEt.Page 34 of 6713424615vlAttorney Docket Number: 2012675-0444
[0144] In some embodiments, Rcis –NHC(CH3)CH2OH. In some embodiments, Rcis–(S)-NHC(CH3)CH2OH. In some embodiments, Rcis -(R)-NHC(CH3)CH2OH. In some embodiments, RcHO-.HO^NSSH. In some embodiments, Rcis OH. In some embodiments, RcisOH OH OHH°N\ HON.,In some embodiments, Rcis H In some embodiments, Rcis H.
[0145] In some embodiments, Rcis -Alaol, wherein the amino group of-Alaol is bonded to the lastH°^A-C(O)- of the peptide backbone (Rcis H ). in some embodiments, Rcis -dAlaol, wherein the HOamino group of -dAlaol is bonded to the last -C(O)- of the peptide backbone (Rcis H ). In some embodiments, Rcis -Prool, wherein the amino group of -Prool is bonded to the last -C(O)- of the peptideQ| |backbone(Rcis ). In some embodiments, Rcis — Throl, wherein the amino group of -Throl is OH HObonded to the last -C(O)- of the peptide backbone (Rcis H ) In some embodiments, Rcis -Serol, wherein the amino group of -Serol is bonded to the last -C(O)- of the peptide backbone (R is HO.
[0146] In some embodiments, Rcis -OH.
[0147] As those skilled in the art appreciate, a compound, agent, etc., may bond to another moiety at various positions, for example, at a position wherein there is ~H. In some embodiments, L° is connected to X1. In some embodiments, L° is connected to X3. In some embodiments, L° is connected to X7. In some embodiments, L° is connected to X8. In some embodiments. L° is connected to X15.
[0148] Agents, peptides, etc., can contain various numbers of amino acid residues. In some embodiments, a length of a peptide is about 5-20, 5-19, 5-18, 5-17, 5-16, 5-15, 10-20, 10-19, 10-18, 10-17, 10-16, 10-15, 11-20, 11-19, 11-18, 11-17, 11-16, 11-15, 12-20, 12-19, 12-18, 12-17, 12-16, 12-15, 13-20, 13-19, 13-18, 13-17, 13-16, 13-15, 14-20, 14-19, 14-18, 14-17, 14-16, 14-15, or about 2, 3, 4, 5, 6, 7, 8. 9, 10, 11, 12. 13. 14, 15, 16, 17, 18, 19, or 20 amino acid residues. In some embodiments, a length is about 10 amino acid residues. In some embodiments, a length is about 11 amino acid residues. In some embodiments.Page 35 of 6713424615vlAttorney Docket Number: 2012675-0444a length is about 12 amino acid residues. In some embodiments, a length is about 13 amino acid residues. In some embodiments, a length is about 14 amino acid residues. In some embodiments, a length is about 15 amino acid residues. In some embodiments, a length is about 16 amino acid residues. In some embodiments, a length is about 17 amino acid residues. In some embodiments, a length is about 18 amino acid residues. In some embodiments, a length is about 19 amino acid residues. In some embodiments, a length is about 20 amino acid residues.
[0149] In some embodiments, as described herein, one or more staples independently comprise an olefin double bond (e.g., formed through olefin metathesis). In some embodiments, one or more staples independently comprise an amide group (e.g., formed through amidation). In some embodiments, at least one staple does not contain an olefin double bond. In some embodiments, there is at least one staple whose formation does not comprise reactions of olefins such as olefin metathesis and / or modification of olefin double bonds (e.g., hydrogenation, epoxidation, etc.).ERG
[0150] Among other things, the present disclosure provides technologies for modulating levels of ETS-related gene (ERG). In some embodiments, the present disclosure provides technologies for modulating one or more ERG functions. In some embodiments, the present disclosure provides technologies for inhibiting one or more ERG functions that are associated with cancer. In some embodiments, provided technologies are useful for preventing and treating conditions, disorders or diseases whose prevention and / or treatment will benefit from reducing levels of ERG polypeptides (e.g., from degradation of ERG polypeptides). In some embodiments, a condition, disorder or disease is cancer.
[0151] ERG is reported to have various functions and according to various reports. According to certain reports, ERG is expressed in the endothelium, hematopoietic stem cells, and adipose tissue. ERG overexpression and / or mutation have been reported to be associated with various conditions, diseases or disorders including cancer. In some embodiments, ERG is overexpressed. In some embodiments, ERG comprises a mutation. In some embodiments, a mutation is or comprises a fusion. In some embodiments, a mutation is or comprises a TMPRSS2-ERG fusion. For example, it is reported that in prostate cancer, N-terminal deleted ERG expression can be driven by AR due to a fusion with the TMPRSS2 promoter.Expression of the ERG fusion has been reported to promote AR binding to a wider range of AR Response Elements, expanding AR functions in the tumor setting. According to certain reports, ERG can also alter gene expression more globally, by promoting sternness through its interactions with chromatin modifying enzymes, such as the BAF complex. This re-purposing of AR and chromatin modifiers has been reported to increase proliferation and migration of these tumor cells. In some embodiments, a TMPRSS2-ERG fusion provides a fusion polypeptide that is or comprises, from its N-terminus to its C-terminus, TMPRSS2 exon 1 and ERG exons 4-11. In some embodiments, a TMPRSS2-ERG fusion increases or promotes proliferation, anti-apoptosis, differentiation, angiogenesis, cell migration, invasion and / or genomic instability.Page 36 of 6713424615vlAttorney Docket Number: 2012675-0444
[0152] It is reported that an estimated 40-50% of all prostate cancers harbor TMPRSS2-ERG fusion, which according to some reports can lead to androgen receptor (AR)-driven expression of the oncogene ERG. According to some reports, TMPRSS2-ERG fusions can appear early in the tumorigenic process and can persist throughout certain treatment regimens. It is reported that, as a transcription factor, ERG can promote tumorigenesis by increasing cell proliferation, invasion and migration of tumor cells, promoting their metastatic ability. According to some reports, ERG and AR can have interconnected roles in prostate cancer, where together they can strike a balance between proliferative potential and luminal differentiation. ERG has also been reported to be able to enhance the sternness of prostate cancer cells, c.g., by interacting with epigenetic modifiers such as EZH2, MAT2A, and the SWI / SNF complex, which may lead to increased therapeutic resistance after treatment with AR targeted therapies. Various ERG oncogenic functions, e.g., proliferation, sternness, aberrant differentiation, altered metabolism, EMT, have been recognized for ERG.
[0153] The lack of ligandable pockets on ERG has previously limited preclinical target validation and development of therapeutic agents targeting ERG. Among other things, the present disclosure provides technologies, e.g., those comprising stapled peptides that can bind ERG, that can be utilized to target ERG. Among other things, the present disclosure demonstrates technologies that can induce targeted ubiquitin-proteosome degradation of ERG by agents comprising an E3-ligase ligand and an ERG Helicon™ binder. Among other things, provided technologies can bind selectively and with high affinity to ERG in biochemical assays. In cells, it is demonstrated that ERG can be degraded using provided agents at low nanomolar potency via an E3-ligase dependent mechanism, reducing expression of its target genes. Using both human cell line- and patient-derived xenograft (PDX) models, it is demonstrated that provided technologies can provide deep and durable degradation of ERG, and that pharmacological reduction of ERG polypeptide levels and ERG target gene expression can lead to substantial tumor growth inhibition.
[0154] In some embodiments, an ERG polypeptide comprises a structured domain. In some embodiments, an ERG polypeptide comprises an ETS domain. In some embodiments, an ERG polypeptide does not comprise an ETS domain. In some embodiments, a polypeptide comprises a PNT domain. In some embodiments, an ERG polypeptide does not comprise a PNT domain. In some embodiments, an ERG polypeptide does not comprise a PNT domain. In some embodiments, an ERG polypeptide comprises an ETS domain and a PNT domain. In some embodiments, a provided technology (e.g., an agent, a target binding moiety, a peptide, PTBM, etc.) can bind to an ETS domain of an ERG. In some embodiments, a provided technology (e.g., an agent, a target binding moiety, a peptide, PTBM, etc.) can bind to a PNT domain of an ERG. In some embodiments, a provided technology (e.g., an agent, a target binding moiety, a peptide, PTBM, etc.) can bind to a polypeptide that is or comprises a full-length ERG (e.g., Pl 1308-4).Linkers
[0155] Various provided agents comprise linkers. In some embodiments, a linker is a covalent bond. In some embodiments, a linker is not a covalent bond. In some embodiments, a linker is bivalent. In some Page 37 of 6713424615vlAttorney Docket Number: 2012675-0444embodiments, a linker is polyvalent. In some embodiments, a linker is bonded to one target binding moiety. In some embodiments, a linker is bonded to two or more target binding moieties. In some embodiments, a linker is bonded to one target binding moiety. In some embodiments, a linker is bonded to two or more target binding moieties. Various linkers including those reported in PROTAC, antibody-drug conjugate technologies, etc., are reported and can be utilized in accordance with the present disclosure.
[0156] In some embodiments, a linker is or comprises L°.L°
[0157] In some embodiments, L° is a covalent bond (absent). In some embodiments, L° is an optionally substituted, bivalent C1-C30 aliphatic group wherein one or more methylene units of the group are each optionally and independently replaced with -C(R’)2-, -Cy- -0- -S-, -S-S-, -N(R’)-, -C(O)-, — C(S)—, -C(NR’)-, -C(0)N(R’)-, -N(R’)C(O)N(R’)-, -N(R’)C(O)O-, -S(O)-, -S(O)2- -S(O)2N(R’)-, -C(O)S--C(O)O-, -(OCH2CH2)n-, or an amino acid residue. In some embodiments, L° is an optionally substituted, bivalent C1-C30 heteroaliphatic group having 1-12 heteroatoms, wherein one or more methylene units of tire group are each optionally and independently replaced with -C(R’)2_, ~Cy~, ~O~, -S-, -S-S-, -N(R’)-, -C(O)-. -C(S)-, -C(NR’)-, -C(0)N(R )-, -N(R )C(0)N(R’)-, -N(R^)C(O)O- -S(O)-, -S(O)2--S(O)2N(R’)-, -C(O)S-, -C(O)O-, -(OCH2CH2)n-, or an amino acid residue. In some embodiments, an aliphatic or heteroaliphatic group is linear. In some embodiments, an aliphatic or heteroaliphatic group is branched. In some embodiments, an aliphatic or heteroaliphatic group comprises one or more rings.E3 Ligase Binding Moieties
[0158] Various provided agents comprise E3 ligase binding moieties. In some embodiments, an E3 ligase binding moiety can bind to an E3 ligase, and can promote ubiquitination of a target polypeptide that a target binding moiety bind and degradation of the target polypeptide. Various E3 ligase binding moieties are reported and can be utilized in accordance with the present disclosure. Certain E3 ligase binding moieties and linkers are reported in US 10905768, US 11407732, US 20190076539, US 20190076540, US 20190076541, US 20190076542, US 20200140456, US 20200207733, US 20200207764, US 20200207783, US 20200308171, US 20200361930, US 20210009559, US 20210032245, US 20210070763, US 20210106688, US 20210198256, US 20220098194, US 20220251061, US 20220289738, US 20220313826, US 20220313827, US 20220372016, US 20230002367, US 20230014124, US 20230019060, US 20230024096, US 20230060334, US 20230082430, US 20230095223, US 20230110648, US 20230145336, US 20230190760, US 20230192643, US 20230233692, US 20230279023, US 20230339902, US 20230357180, US 20230372496, US 20230416251, US 20240018156, US 20240051953, US 20240076300, US 20240109889, WO 2017 / 197036, WO 2017 / 197046, WO 2017 / 197051, WO 2017 / 197055, WO 2017 / 197056, WO 2018 / 220149, WO 2018 / 237026, WO 2019 / 043208, WO 2019 / 043214, WO 2019 / 043217, WO 2019 / 099868, WO 2019 / 121562, WO 2019 / 149922, WO 2019 / 191112, WO 2019 / 204354, WO Page 38 of 6713424615vlAttorney Docket Number: 2012675-04442019 / 236483, WO 2020 / 051235, WO 2020 / 132561, WO 2020 / 181232, WO 2020 / 210630, WO 2021 / 083949, WO 2021 / 086785, WO 2021 / 127561, WO 2021 / 178920, WO 2021 / 255212, WO 2021 / 255213, WO 2022 / 032026, WO 2022 / 032132, WO 2022 / 081925, WO 2022 / 081927, WO 2022 / 081928, WO 2022 / 235945, WO 2022 / 251539. WO 2022 / 261250, WO 2023 / 039208, WO 2023 / 055952. WO 2023 / 154417, WO 2023 / 239750, WO 2023 / 244764, WO 2023 / 283372. and WO 2023 / 283610, the E3 ligase binding moieties and linkers of each of which are independently incorporated herein by reference.
[0159] In some embodiments, an E3 ligase binding moiety is LBM as described herein which can bind an E3 ligase.LBM
[0160] In some embodiments, LBM is an E3 ligase binding moiety. In some embodiments, an E3 ligase is CRBN, VHL, UBR4, KLHDC2, KEAP1, XIAP, or RNF126. In some embodiments, LBM is an E3 ligase binding moiety that binds to CRBN, VHL, UBR4, KLHDC2, KEAP1, XIAP, or RNF126. In some embodiments, LBM binds to CRBN. In some embodiments, LBM binds to VHL. In some embodiments, LBM binds to UBR4. In some embodiments, LBM binds to KLHDC2. In some embodiments, LBM binds to KEAP1. In some embodiments. LBM binds to XIAP. In some embodiments. LBM binds to RNF126. In some embodiments, an agent comprising LBM can bind an E3 ligase, and can promote ubiquitination of a target polypeptide that a target binding moiety bind and degradation of the target polypeptide.Characterization
[0161] In some embodiments, agents are characterized with respect to, for example, one or more characteristics such as binding characteristics - e.g., with respect to a particular target of interest (e.g.. ERG or a portion thereof), stability characteristics, for example in solution or in dried form, cell permeability characteristics, solubility, lipophilicity, ubiquitination and / or degradation of a target agent (e.g., ERG), etc.
[0162] In some embodiments, a binding characteristic may be or comprise specificity, affinity, on-rate, off-rate, etc., optionally under (or over a range of) specified conditions such as, for example, concentration, temperature, pH. cell type, presence or level of a particular competitor, etc.
[0163] As will be appreciated by those skilled in the art, assessments of characteristics as described herein may involve comparison with an appropriate reference (e.g., a positive or negative control) which may, in some embodiments, be a contemporaneous reference or, in some embodiments, a historical reference. In some embodiments, comparison is to a reference agent, e.g., an agent without a linker and / or a E3 ligase binding moiety, PTBM, [PTBM]-L°-H, etc. In some embodiments, an agent can bind an E3 ligase while a reference agent cannot.
[0164] In some embodiments, desirable characteristics may be. for example: binding to a desired target (e.g., a dissociation constant (KD) of at least less than about 1 pM, and preferably a KD of less than about 50 nM); cell penetration (e.g., as measured by fluorescence-based assays or mass spectrometry of cellular Page 39 of 6713424615vlAttorney Docket Number: 2012675-0444fractions, etc.); activity (e.g., modulating one or more functions of a target, which may be assessed in a cellular reporter assay (e.g., with an IC50 of less than a concentration, e.g., less than about 1 pM, less than about 500 nM, less than about 50 nM, less than about 10 nM, etc.), an / or an animal model (e.g., various animal models for conditions, disorders or diseases; stability, etc. In some embodiments, an agent of the invention comprises an affinity of less than about 100 or 10 nM.
[0165] In some embodiments, provided agents can bind to targets with an EC 50 of no more than about 2000 nM. In some embodiments, provided agents can bind to an E3 ligase with an EC 50 of no more than about 2000 nM. In some embodiments, provided agents can reduce ERG levels with an EC 50 of no more than about 2000 nM. In some embodiments, provided agents can inhibit cell growth, e.g., cancer cell growth, with an EC 50 of no more than about 2000 nM. In some embodiments, an EC50 is about or no more than about 1500 nM. In some embodiments, an EC50 is about or no more than about 1000 nM. In some embodiments, an EC50 is about or no more than about 500 nM. In some embodiments, an EC50 is about or no more than about 300 nM. In some embodiments, an EC50 is about or no more than about 200 nM. In some embodiments, an EC50 is about or no more than about 100 nM. In some embodiments, an EC50 is about or no more than about 50 nM. In some embodiments, an EC50 is about or no more than about 10 nM. In some embodiments, an EC50 is measured by fluorescence polarization or another technology in tire Examples.Production
[0166] Various technologies are known in the art for producing provided agents. For example, various technologies for preparing small molecules, peptides (including stapled peptides) may be utilized in accordance with the present disclosure. Those skilled in the art, reading the present disclosure will well appreciate which such technologies are applicable in which aspects of the present disclosure in accordance with the present disclosure. Certain useful technologies for manufacturing peptide agents, e.g., stapled peptide agents, are described in WO 2022 / 020651, WO 2022 / 020652 and WO 2022 / 261257, the entirety of each of which is incorporated herein by reference.
[0167] Properties and / or activities of provided stapled peptides can be readily assessed in accordance with the present disclosure, for example, through use of one or more methods described in the examples.
[0168] In some embodiments, technologies for preparing and / or assessing provided stapled peptides include those described in US 9617309, US 20150225471, US 20160024153, US 20160215036,US20160244494, WO 2017 / 062518, etc.
[0169] In some embodiments, after production a peptide, e.g., PTBM, is conjugated with a target binding moiety or LBM through a linker. Various useful technologies are reported and can be utilized in accordance with the present disclosure. Certain such technologies are illustrated in the Examples.
[0170] In some embodiments, the present disclosure provides products manufactured and / or characterized by processes and / or technologies described herein.Page 40 of 6713424615vlAttorney Docket Number: 2012675-0444
[0171] Provided compounds can be provided in high purity. In some embodiments, a provided compound is at least about 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% pure. In some embodiments, provided compounds, e.g., amino acids optionally protected / activated, are essentially free of impurities, including stereoisomers. In some embodiments, purity is by wt%. In some embodiments, purity is by mol%.
[0172] In some embodiments, an agent may have one or more stereoisomers which may independently co-exist in a composition or preparation. In some embodiments, a provided agent has a stereopurity of about or at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%. In some embodiments, it is about or at least about 80%. In some embodiments, it is about or at least about 85%. In some embodiments, it is about or at least about 90%. In some embodiments, it is about or at least about 95%. In some embodiments, it is about or at least about 96%. In some embodiments, it is about or at least about 97%. In some embodiments, it is about or at least about 98%. In some embodiments, it is about or at least about 99%. In some embodiments, stereoisomers are essentially free from a preparation or composition (e.g., cannot be reliably observed in NMR or HPLC). In some embodiments, an agent comprises one or more staples independently comprising one or more olefin double bond. In some embodiments, stereopurity is with respect to E / Z stereoisomers. In some embodiments, for one or more (e.g., 1, 2, 3, 4. 5 or more) or each olefin double bond in a staple, the ratio of the two stereoisomers is independently about 1.1:1, 1.2: 1, 1.3:1, 1.4:1, 1.5:1, 2:1, 3:1, 4:1, 5:1, 10:1, 20:1, 30:1, 40:1, 50:1, 60:1, 70:1, 80:1, 90:1, 100:1 or more. In some embodiments, it is independently about 1.5:1 or more. In some embodiments, it is independently about 2: 1 or more. In some embodiments, it is independently about 3: 1 or more. In some embodiments, it is independently about 4: 1 or more. In some embodiments, it is independently about 5: 1 or more. In some embodiments, it is independently about 6: 1 or more. In some embodiments, it is independently about 7: 1 or more. In some embodiments, it is independently about 8: 1 or more. In some embodiments, it is independently about 9: 1 or more. In some embodiments, it is independently about 10:1 or more. In some embodiments, it is independently about 20: 1 or more. In some embodiments, it is independently about 30: 1 or more. In some embodiments, it is independently about 40: 1 or more. In some embodiments, it is independently about 50: 1 or more. In some embodiments, it is independently about 60: 1 or more. In some embodiments, it is independently about 70: 1 or more. In some embodiments, it is independently about 80: 1 or more. In some embodiments, it is independently about 90: 1 or more. In some embodiments, it is independently about 100: 1 or more. In some embodiments, a ratio is E. Z. In some embodiments, a ratio is Z: E. Those skilled in the art appreciate that E and Z isomers may be selectively enriched through modulating manufacturing processes, purification, staple positioning and / or lengths, etc.Compositions
[0173] Among other things, the present disclosure provides compositions that comprise or otherwise relate to provided agents, e.g., small molecule agents, peptide agents (e.g., stapled peptide agents), as Page 41 of 6713424615vlAttorney Docket Number: 2012675-0444described herein.
[0174] In some embodiments, provided compositions are or comprise an assay system for characterizing (and optionally including) a stapled peptide as described herein.
[0175] In some embodiments, provided compositions are pharmaceutical compositions e.g., that comprise or deliver one or more provided agents. In some embodiments, the present disclosure provides a pharmaceutical composition, comprising an agent as described herein and a pharmaceutically acceptable carrier. In some embodiments, an agent is in a salt form. In some embodiments, an agent is in a pharmaceutically acceptable salt form. In some embodiments, in a composition, e.g., a buffered liquid composition, an agent may be in multiple forms, e.g., an acid form, a base form, a salt form, etc. In some embodiments, a composition comprises multiple salt fonns, e.g., multiple pharmaceutically acceptable salt forms, of an agent. In some embodiments, a pharmaceutically acceptable carrier is or comprises a buffer. In some embodiments, a pharmaceutically acceptable carrier is or comprises a phosphate buffer. In some embodiments, a pharmaceutically acceptable carrier is or comprises a phosphate saline buffer. In some embodiments, pH of a buffer or a pharmaceutical composition is about 7.
[0176] In some embodiments, an agent is or comprises a peptide. In some embodiments, an agent is or comprises a stapled peptide. For example, in some embodiments, an agent has the structure ofTBM-L "-LBM as described herein, wherein TBM is or comprises a peptide moiety.
[0177] In some embodiments, a pharmaceutical composition comprises a provided agent and a pharmaceutically acceptable excipient (e.g., carrier).
[0178] In some embodiments, a peptide composition may include or deliver a particular fonn (e.g., a particular optical isomer, diastereomer, salt form, covalent conjugate fonn [e.g., covalently attached to a carrier moiety], etc., or combination thereof) of an agent as described herein). In some embodiments, an agent included or delivered by a pharmaceutical composition is described herein is not covalently linked to a carrier moiety.
[0179] In some embodiments, a provided therapeutic composition may comprise one or more additional therapeutic agents and / or one or more stabilizing agents and / or one or more agents that alters (e.g., extends or limits to a particular tissue, location or site) rate or extent of delive ry over time.
[0180] In some embodiments, a composition is a pharmaceutical composition which comprises or delivers a provided agent (e.g., a stapled peptide agent) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient. In some embodiments, a composition comprises one and only stereoisomer of an agent (e.g., a stapled peptide agent) and / or one or more salts thereof. In some embodiments, a composition comprises two or more stereoisomers of an agent (e.g., a stapled peptide agent) and / or one or more salts thereof. In some embodiments, the two or more stereoisomers of an agent (e.g., a stapled peptide agent) or salts thereof elute as a single peak (e.g., UV and / or MS detection) in a chromatography, e.g., HPLC.Page 42 of 6713424615vlAttorney Docket Number: 2012675-0444Uses and Applications
[0181] Provided agents and compositions can be utilized for various purposes. For example, certain agents and compositions thereof are biologically active and can be utilized for various purposes, e.g., as therapeutics toward various conditions, disorders or diseases, as tools for modulating biological functions, etc.
[0182] In some embodiments, the present disclosure provides agents and compositions thereof for modulating ERG functions. In some instances, ERG is reported to have multiple cellular functions and is expressed in the endothelium, hematopoietic stem cells, and adipose tissue. In some embodiments, agents described herein may inhibit ERG activity and / or level and may, for example, inhibit neoplastic growth. In some embodiments, provided technologies can provide on target, specific degradation of ERG polypeptide.
[0183] In some embodiments, provided technologies can inhibit cell growth. In some embodiments, provided technologies can inhibit cell proliferation. In some embodiments, the present disclosure provides a method for inhibiting cell growth in a system, comprising administering or delivering to the system an agent or a composition thereof. In some embodiments, the present disclosure provides a method for inhibiting cell proliferation in a system, comprising administering or delivering to tire system an agent or a composition thereof. In some embodiments, cell growth and / or proliferation is ERG dependent.
[0184] In some embodiments, the present disclosure provides a method for increasing ubiquitination of ERG polypeptide in a system, comprising administering or delivering to the system an agent or a composition thereof. In some embodiments, the present disclosure provides a method for reducing ERG polypeptide level in a system, comprising administering or delivering to the system an agent or a composition thereof. In some embodiments, the present disclosure provides a method for modulating ERG-driven transcription in a system, comprising administering or delivering to the system an agent or a composition thereof.
[0185] In some embodiments, the present disclosure provides a method for reducing cell proliferation, invasion, or migration. In some embodiments, the present disclosure provides a method for reducing cell proliferation, invasion, or migration in a system, comprising administering or delivering to the system an agent or a composition thereof. In some embodiments, the present disclosure provides a method for reducing an ERG oncogenic function, e g., proliferation, sternness, aberrant differentiation, altered metabolism, EMT, in a system, comprising administering or delivering to the system an agent or a composition thereof.
[0186] In some embodiments, the present disclosure provides a method for providing cell cycle arrest. In some embodiments, the present disclosure provides a method for providing cell cycle arrest in a system, comprising administering or delivering to the system an agent or a composition thereof. In some embodiments, provided technologies can modulate the cell cycle. In some embodiments, the present disclosure provides a method for reducing S-phase population of cells in a system, comprising administering or delivering to the system an agent or a composition thereof. In some embodiments, the present disclosure provides a method for increasing Go / Gi-phase population of cells in a system, comprising administering or delivering to the system an agent or a composition thereof. In some embodiments, the present disclosure Page 43 of 6713424615vlAttorney Docket Number: 2012675-0444provides a method for reducing S-phase population of cells in a system in the presence of an androgen, comprising administering or delivering to the system an agent or a composition thereof. In some embodiments, the present disclosure provides a method for increasing Go / Gi-phase population of cells in a system in the presence of an androgen, comprising administering or delivering to the system an agent or a composition thereof. In some embodiments, an androgen is testosterone or DHT. In some embodiments, an androgen is DHT. Tn some embodiments, the present disclosure provides a method for increasing G0 / Gi-phase population of cells in a system, comprising administering or delivering to the system an agent or a composition thereof.
[0187] In some embodiments, the present disclosure provides a method for modulating expression of a nucleic acid (e.g., a gene). In some embodiments, the present disclosure provides a method for modulating expression of a nucleic acid (e.g., a gene) in a system, comprising administering or delivering to the system an agent or a composition thereof. In some embodiments, a nucleic acid is or comprises an ERG target gene. In some embodiments, the present disclosure provides a method for modulating ERG target gene expression. In some embodiments, the present disclosure provides a method for modulating ERG target gene expression in a system, comprising administering or delivering to the system an agent or a composition thereof. In some embodiments, an ERG target gene is ARHGDIB. In some embodiments, a nucleic acid is or comprises a Myc target gene. In some embodiments, the present disclosure provides a method for modulating a Myc target gene expression. In some embodiments, the present disclosure provides a method for modulating a Myc target gene expression in a system, comprising administering or delivering to tire system an agent or a composition thereof. In some embodiments, expression is downregulated. In some embodiments, expression of an ERG target gene is downregulated. In some embodiments, expression of a Myc target gene is downregulated. In some embodiments, a nucleic acid is in Hallmark Myc Targets V2.
[0188] In some embodiments, the present disclosure provides a method for inhibiting tumor growth. In some embodiments, the present disclosure provides a method for inhibiting tumor growth in a system, comprising administering or delivering to the system an agent or a composition thereof.
[0189] In some embodiments, a provided technology is proteosome-dependent. In some embodiments, a provided technology is less effective in tire presence of a proteosome inhibitor when the inhibitor is at or above its effective concentration. In some embodiments, a proteosome inhibitor is bortezomib. In some embodiments, a provided technology is less effective in the presence of an E3 ligand. For example, in some embodiments, reduction of ERG levels is less in the presence of a proteosome inhibitor and / or an E3 ligand. In some embodiments, a provided technology is selective for a target, e.g., an ERG polypeptide. In some embodiments, a provided technology does not significantly reduce levels of one or more other polypeptides.
[0190] In some embodiments, a system is an in vitro system. In some embodiments, a system is an in vivo system. In some embodiments, a system is or comprises a sample. In some embodiments, a system is or comprises a cell, tissue or organ. In some embodiments, a system is or comprises a cell. In some embodiments, a cell is a cancer cell. In some embodiments, a cell is a prostate cancer cell. In some Page 44 of 6713424615vlAttorney Docket Number: 2012675-0444embodiments, a system is or comprises a tissue. In some embodiments, a system is or comprises an organ. In some embodiments, a system is or comprises a tumor. In some embodiments, a system is or comprises a cell-derived xenograft (CDX). In some embodiments, a system is or comprises a VCaP xenograft. In some embodiments, a system is or comprises a patient-derived xenograft (PDX). In some embodiments, a system is or comprises a mCRPC xenograft. In some embodiments, a system is or comprises a mCRPC PDX xenograft. In some embodiments, a system is or comprises a VCaP CDX NSG mice. In some embodiments, a system is or comprises a VCaP CDX eugonadal mouse. In some embodiments, a system is or comprises a VCaP CDX hypogonadal mouse. In some embodiments, a system is or comprises a mCRPC PDX eugonadal mouse. In some embodiments, a system is a subject.
[0191] In some embodiments, the present disclosure provides method for inhibiting cell grow th, comprising administering or delivering to a population of cells a provided agent or a pharmaceutically acceptable salt thereof. In some embodiments, the present disclosure provides method for killing cells associated with a condition, disorder or disease (e.g., cancer), comprising administering or delivering to a population of such cells a provided agent or a pharmaceutically acceptable salt thereof.
[0192] In some embodiments, a system, cell, tissue, organ or subject comprises or expresses a mutant ERG. In some embodiments, a cell is a prostate cell that comprises or expresses a mutant ERG. In some embodiments, a cell is a prostate cancer cell that comprises or expresses a mutant ERG. In some embodiments, a system, tissue, organ or subject comprises a prostate cell that comprises or expresses a mutant ERG. In some embodiments, a system, cell, tissue, organ or subject comprises a prostate cancer cell that comprises or expresses a mutant ERG. For example, in some embodiments, a mutation is a fusion mutation. In some embodiments, a mutation is a TMPRSS2-ERG fusion. In some embodiments, a mutation is associated with a condition, disorder or disease, e.g., cancer (e.g., prostate cancer).
[0193] In some embodiments, the present disclosure provides methods for preventing a condition, disorder or disease associated with ERG (e.g., a cancer, etc ), comprising administering or delivering to a subject susceptible thereto a provided agent or a pharmaceutically acceptable salt thereof. In some embodiments, the present disclosure provides methods for treating a condition, disorder or disease associated with ERG (e.g., aberrant ERG activity and / or expression level), comprising administering or delivering to a subject suffering therefrom a provided agent or a pharmaceutically acceptable salt thereof. In some embodiments, a provided agent is administered as a pharmaceutical composition that comprises or delivers a provided agent or a pharmaceutically acceptable salt thereof. In some embodiments, a condition, disorder or disease is cancer. In some embodiments, provided agents may be administered in combination with another therapy, e.g., immunotherapy. In some embodiments, a condition, disorder, or disease is selected from cancer, cardiac disease, dilated cardiomyopathy, fetal alcohol syndrome, depression, and diabetes. In some embodiments, a condition, disorder, or disease is a heart condition, disorder, or disease. In some embodiments, a condition, disorder, or disease is cancer. In some embodiments a cancer is prostate cancer. In some embodiments, a subject comprises a mutation in ERG, e.g. a TMPRSS2 fusion. In somePage 45 of 6713424615vlAttorney Docket Number: 2012675-0444embodiments, a subject comprises a TMPRSS2-ERG fusion mutation. In some embodiments, a subject comprises or expresses mutant ERG, e.g., TMPRSS2-ERG fusion protein. In some embodiments, a mutant ERG is or is expressed in a prostate cell. In some embodiments, a mutant ERG is or is expressed in a cancer cell. In some embodiments, a mutant ERG is or is expressed in a prostate cancer cell. In some embodiments, mutations in ERG are present in cells, models, tissues, organs, systems, subjects, etc., with other mutations, e.g., those associated with various conditions, disorders or diseases such as cancer.
[0194] In some embodiments, comparison is made to a reference. For example, reduction, increase, enrichment (negative or positive), changes, etc., arc typically made to a suitable reference. In some embodiments, reduction, increase, enrichment (negative or positive), changes, etc., are to a reference assessment, in some embodiments, of a reference sample. In some embodiments, a reference assessment is or comprises assessment conducted prior to an administration or delivery of an agent. In some embodiments, a reference sample is collected prior to an administration or delivery of an agent. In some embodiments, a reference assessment is or comprises assessment conducted during an administration or delivery of an agent. In some embodiments, a reference sample is collected during an administration or deliver}’ of an agent. In some embodiments, a reference assessment is or comprises assessment conducted after an administration or delivery of an agent. In some embodiments, a reference sample is collected after an administration or delivery of an agent. In some embodiments, a reference assessment is or comprises assessment conducted after an earlier administration or delivery of an agent. In some embodiments, a reference sample is collected after earlier an administration or delivery of an agent. In some embodiments, a reference does not reduce level of ERG. In some embodiments, a reference agent does not bind to an E3 ligase.
[0195] In some embodiments, a sample is an aliquot of material obtained or derived from a source of interest as described herein. In some embodiments, a source of interest is a biological or environmental source. In some embodiments, a source of interest may be or comprise a cell or an organism, such as a microbe, a plant, or an animal (e.g., a human). In some embodiments, a source of interest is or comprises biological tissue or fluid. In some embodiments, a biological tissue or fluid may be or comprise amniotic fluid, aqueous humor, ascites, bile, bone marrow, blood, breast milk, cerebrospinal fluid, cerumen, chyle, chime, ejaculate, endolymph, exudate, feces, gastric acid, gastric juice, lymph, mucus, pericardial fluid, perilymph, peritoneal fluid, pleural fluid, pus, rheum, saliva, sebum, semen, serum, smegma, sputum, synovial fluid, sweat, tears, urine, vaginal secretions, vitreous humour, vomit, and / or combinations or component(s) thereof. In some embodiments, a biological fluid may be or comprise an intracellular fluid, an extracellular fluid, an intravascular fluid (blood plasma), an interstitial fluid, a lymphatic fluid, and / or a transcellular fluid. In some embodiments, a biological fluid may be or comprise a plant exudate. In some embodiments, a biological tissue or sample may be obtained, for example, by aspirate, biopsy (e.g., fine needle or tissue biopsy), swab (e.g., oral, nasal, skin, or vaginal swab), scraping, surgery, washing or lavage (e.g., brocheoalvealar, ductal, nasal, ocular, oral, uterine, vaginal, or other washing or lavage). In some embodiments, a biological sample is or comprises cells obtained from an individual. In some embodiments, a Page 46 of 6713424615vlAttorney Docket Number: 2012675-0444sample is a 'primary sample” obtained directly from a source of interest by any appropriate means. In some embodiments, as will be clear from context, the temr “sample” refers to a preparation that is obtained by processing (e.g., by removing one or more components of and / or by adding one or more agents to) a primary sample. For example, filtering using a semi-permeable membrane. Such a “processed sample” may comprise, for example nucleic acids or proteins extracted from a sample or obtained by subjecting a primary sample to one or more techniques such as amplification or reverse transcription of nucleic acid, isolation and / or purification of certain components, etc. In some embodiments, a sample comprise cancer cells. In some embodiments, a sample is obtained from a tumor. In some embodiments, a sample is obtained from a tumor in a patient.
[0196] Various technologies can be utilized in accordance with the present disclosure to formulate, distribute, administer or deliver provided technologies such as agents, peptides, compounds, compositions, etc. For example, in some embodiments, administration may be ocular, oral, parenteral, topical, etc. In some particular embodiments, administration may be bronchial (e.g., by bronchial instillation), buccal, dermal (which may be or comprise, for example, one or more of topical to the dermis, intradermal, intcrdcnnal, transdemial, etc), enteral, intra-arterial, intradermal, intragastric. intramedullary, intramuscular, intranasal, intraperitoneal, intrathecal, intravenous, intraventricular, within a specific organ (e. g.. intrahepatic). mucosal, nasal, oral, rectal, subcutaneous, sublingual, topical, tracheal (e.g., by intratracheal instillation), vaginal, vitreal, etc. In some embodiments, administration may involve dosing that is intermittent (e.g., a plurality of doses separated in time) and / or periodic (e.g., individual doses separated by a common period of time) dosing. In some embodiments, administration may involve continuous dosing (e.g., perfusion) for at least a selected period of time. In some embodiments, provided technologies are administered intravenously.
[0197] Among other things, the present disclosure provides various structural moieties including designed amino acid residues that can be utilized to optimize various properties and activities, stability, delivery, pharmacodynamics, pharmacokinetics, etc. to provide various dosage forms, dosage regimen, therapeutic windows, etc. In some embodiments, provided agents and compositions thereof may be utilized with improved dosage regimen and / or unit doses. In some embodiments, administration of provided agents are adjusted based on conditions, disorders or diseases and / or subpopulations. In some embodiments, administration and / or dosage regimen of provided technologies are adjusted according to certain biomarkers and genomic alterations.
[0198] Provided agents may deliver biological effects, e.g., therapeutic effects, via various mechanisms. In some embodiments, efficacy may be driven by AUC. In some embodiments, efficacy may be driven by Cmax.
[0199] In some embodiments, a provided agent is utilized in combination with another therapy. In some embodiments, a provided agent is utilized in combination with another therapeutic agent. In some embodiments, another therapy or therapeutic agent is administered prior to an administration or delivery of a provided agent. In some embodiments, another therapy or therapeutic agent is administered at about the Page 47 of 6713424615vlAttorney Docket Number: 2012675-0444same time as an administration or delivery of a provided agent. In some embodiments, a provided agent and another agent is in the same pharmaceutical composition. In some embodiments, another therapy or therapeutic agent is administered subsequently to an administration or delivery of a provided agent. In some embodiments, a subject is exposed to both a provided agent and another therapeutic agent. In some embodiments, both a provided agent and another agent can be detected in a subject. In some embodiments, a provided agent is administered before another agent is cleared out by a subject or vice versa. In some embodiments, a provided agent is administered within the half-life, or 2, 3, 4, 5 or 6 times of the half-life, of another agent or vice versa. In some embodiments, a subject is exposed to a therapeutic effect of a provided agent and a therapeutic effect of another therapeutic agent. In some embodiments, an agent may provide an effect after an agent is cleared out or metabolized by a subject. In some embodiments, a procedure, e.g., surgery, radiation, etc., may provide an effect after the procedure is completed.
[0200] In some embodiments, another therapy is a cancer therapy. In some embodiments, another therapy is or comprises surgery. In some embodiments, another therapy is or comprises radiation therapy. In some embodiments, another therapy is or comprises immunotherapy. In some embodiments, another therapeutic agent is or comprises a drug. In some embodiments, another therapeutic agent is or comprises a cancer drug. In some embodiments, another therapeutic agent is or comprises a chemotherapeutic agent. In some embodiments, another therapeutic agent is or comprises a hormone therapy agent. In some embodiments, another therapeutic agent is or comprises an androgen receptor pathway inhibitor. In some embodiments, another therapy is androgen deprivation treatment. In some embodiments, another therapeutic agent is or comprises enzalutamide. In some embodiments, another therapeutic agent is or comprises abiraterone. In some embodiments, another therapeutic agent is or comprises an inhibitor of an ERG interactor. In some embodiments, another therapeutic agent is or comprises an epigenetic target inhibitor (e.g., PRC2 (EZH2 / EED)). In some embodiments, another therapeutic agent is or comprises a PRC2 inhibitor. In some embodiments, a combination is independent of AR pathway inhibition. Investigations can be conducted to assess whether provided ERG-degrading agents, alone or with PRC2 inhibitors, can serve as frontline therapy for hormone-sensitive prostate cancer patients before initiating androgen deprivation treatment (ADT).EXEMPLIFICATION
[0201] Those skilled in the art appreciate that various technologies are available for manufacturing and assessing provided agents in accordance with the present disclosure, for example, many technologies for preparing small molecules and peptides can be utilized to prepare provided agents, and various assays are available for assessing properties and / or activities of provided agents. Described below are certain such useful technologies. Certain useful technologies are described in, e.g., WO 2022 / 020652 and WO 2022 / 261257.
[0202] Example 1. Preparation of various compounds.Page 48 of 6713424615vlAttorney Docket Number: 2012675-0444
[0203] Among other things, peptides can be prepared using various peptide synthesis technologies in accordance with the present disclosure. In many embodiments, peptides were prepared using Fmoc-based synthesis, often on suitable solid phase. For various stapled peptides, amino acid residues were stapled through suitable chemistry, e.g., olefin metathesis for amino acids that comprise olefin groups. Those skilled in the art appreciates that other suitable technologies may also be utilized for stapling in accordance with the present disclosure, e.g., those described in WO / 2019 / 051327, WO / 2020 / 041270, WO 2022 / 020651, WO 2022 / 020652, WO 2022 / 261257, etc., the peptide staples and technologies for preparing peptides are incorporated herein by reference. In some embodiments, peptides were synthesized on a Syro automated peptide synthesizer on Rink amide resin (-0.5 mmol / g loading).
[0204] Among other things, various agents comprising stapled peptides are designed and manufactured. As described in Example 2 below, various agents can provide various activities, e.g., binding to ERG and / or E3 ligase, reducing levels of ERG polypeptide levels, inhibiting proliferation, inhibiting tumor growth, modulating ERG target gene expression, etc.
[0205] Example 2. Provided technologies can provide various activities.
[0206] Among other things, the present disclosure demonstrates technologies targeting ERG including technologies that can target ERG for degradation. Various activities and functions are described herein as examples.
[0207] For example, it is demonstrated that agents, which comprise stapled peptides and can bind to ERG and E3 ligases, can reduce levels of ERG polypeptide. Certain observations are provided in Figure 1, Figure 2, Figure 3, Figure 4, and Figure 5. As shown, reduction of ERG polypeptide level can be dependent on E3 ligase and on proteosome. See, e.g., in the presence of bortezomib (Figure 1), knockdown of E3-ligase (Figure 2). in tire presence of MLN4924 (Figure 3), and in the presence of an E3 ligase (Figure 4). Among other things, provided technologies can also reduce ERG polypeptide level and inhibit tumor growth in vivo. See, e.g., Figure 5 and Figure 6.
[0208] Various agents have been designed and prepared to demonstrate and confirm various properties, functions, activities, benefits, advantages, improvements, etc. of provided technologies. For example, Agent 3 comprises a stapled peptide that binds to ERG and an E3 ligand. Agent 4 comprises an inactive stereoisomer of the E3 ligand in Agent 3 but is otherwise structurally identical to Agent 3. Agent 5 comprises the same stapled peptide as that in Agent 3 and no E3 ligand. Agent 6 comprises a lower-affinity stapled peptide that binds to ERG (compared to that in Agent 3) and an E3 ligand.
[0209] As described herein, the present disclosure provides technologies that can reduce ERG levels, and / or can inhibit cell proliferation, including in cells comprising TMPRSS2-ERG fusion. In some embodiments, a provided technology comprises RNA knockdown, e.g., shRNA. For example, in an assessment, shRNA with either a non-targeting or an ERG targeting (5'-GCGTGTGATTGTAGACAGAGGctCHGAgCCTCTGTCTACAATCACACGC-3') sequence was cloned into pLKO-Tet-On-puro. Lentivirus was generated and VCaP cells were infected and selected w ith Page 49 of 6713424615vlAttorney Docket Number: 2012675-0444puromycin for 2 weeks. Cells were treated with 200 ng / mL doxycycline for 7 days, with the media replenished every 2-3 days. Western blot was run for ERG (Biocare Medical ACR421A) and GAPDH (Millipore MAB374), and reduction of ERG polypeptide levels were confirmed. Certain results were provided in Figure 1A. Among other things, the present disclosure demonstrates that reduction of ERG can reduce cell proliferation including in prostate cancer cells comprising TMPRSS2-ERG fusion. Certain observations are provided in Figure 7B. In a 21 -day colony formation assessment, stable DOX (doxycycline) inducible sh-nontargeting or sh-ERG expressing VCaP cells were plated at 5000 cells / well in a 6-well plate. Media was changed every 5-6 days over the course of 21-days. At day 21, cells were washed with PBS, fixed with PFA, and stained with crystal violet. Colonies were imaged and quantified using Licor Odyssey. As demonstrated in Figure 7B, provided technologies can reduce cell proliferation.
[0210] As confirmed herein, provided technologies can bind ERG. Various technologies can be utilized to assess binding including affinity in accordance with the present disclosure. In an assessment, recombinant full-length ERG isoform 1 (Pl 1308-4) was expressed in E. coli and purified via IMAC affinity. Tire protein was labeled on tire N-tcrminus with PEG12-biotin and further purified with preparative SEC and cation exchange chromatography. ERG protein was immobilized on a streptavidin sensor chip and helicons were flowed over the surface at varying concentrations. Tire resulting data was double-referenced and fit to appropriate kinetic binding models. All SPR assays were run on Biacore instruments. Certain observations are provided in Figure 8. The following KDvalues were measured: Agent 3: 9 nM; Agent 4: 18 nM; Agent 5: 9 nM; Agent 6: >1000 nM. Among other things, provided technologies can exhibit nanomolar affinity for ERG. Certain observations are provided in Figure 8.
[0211] Among other things, certain provided technologies were assessed using REH ERG-HIBIT. CRISPR / Cas9 was used to generate REH cells (ATCC CRL-8286) with C-terminally HiBiT-tagged endogenous ERG. The REH ERG-HiBiT cells were plated and treated with decreasing concentration of agents in 4% FBS Optimem. 24 hrs later, HiBiT luminescence was detected, and multiplexed CTG 2.0 (Promega) was used to confirm there were no effects on viability. Protein levels were normalized to background luminescence and total luminescence in vehicle treated samples. Each plate was confirmed to exhibit Z’ >0.5. Tire following DC50 values were measured: Agent 3: 15 nM; Agent 4: >10000 nM; Agent 5: >10000 nM: Agent 6: 4120 nM. Among other things, provided technologies can reduce levels of ERG polypeptides. Certain observations are provided in Figure 9.
[0212] As confirmed herein, provided technologies can reduce expression of various nucleic acids, e.g., ERG-target genes. Among other things, qPCR was utilized to assess RNA levels. In certain assessments, in culture, VCaP cells (ATCC CRL-2876) were plated in 4% FBS, DMEM and then treated with agents for 24 h. For in vivo tumor samples, tumor samples were collected and washed in PBS and a 20 mg piece of tumor was pulverized. RNA was extracted using the RNeasy 96 kit (Qiagen 74181), cDNA was synthesized (Applied Biosystems #4387406), and qPCR was run using Taqman probes for ARHGDIB (Thermo Fisher Scientific 4331182 Hs00171288_ml FAM) as an example of a target gene and ACTB (Thermo Fisher Page 50 of 6713424615vlAttorney Docket Number: 2012675-0444Scientific 4448489 Hs01060665_g1 VIC) as a housekeeping control. Data was analyzed using a standard ddCt method wherein vehicle is used as the control. Certain results were presented in Figure 10, wherein the following IC50 values were observed for reduction of AEHGDIB expression in VCaP cells: Agent 3: 9 nM; Agent 4: >1000 nM: Agent 5: >1000 nM; Agent 6: >1000 nM. As demonstrated herein, provided technologies can reduce expression of ERG target genes, e.g., ARHGD1B.
[0213] Among other things, provided technologies can reduce cancer cell proliferation. For example, in an assessment, proliferation of VCaP cells was assessed and confirmed. VCaP cells were plated in 10% FBS, DMEM at 10,000 cells per 96-well plate. The next day, they were treated with 10 nM DHT plus a dose of an agent. A Day 0 Cell Titer-Gio 2.0 (CTG) (Promega G9241) plate was read out on a luminescence plate reader to determine baseline amount of cells. 14 days later, the plate was read out for CTG. Data was analyzed by determining total luminescence in treated wells compared to control, vehicle treated wells. In an assessment, the following GEo values were measured: Agent 3: 100 nM; Agent 4: >10000 nM; Agent 5: >10000 nM; Agent 6: >10000 nM. Among other things, provided technologies can reduce viability of cancer cells and exhibit anti -proliferative effects. Certain observations arc provided in Figure 11.
[0214] Reduction of ERG levels can be assessed by and was confirmed by Western Blot. A useful procedure is described herein as an example. Cells or tumors were lysed in protease and phosphatase inhibitor containing Pierce IP / Lysis buffer (Thermo Scientific PI87788) or RIPA. Membranes and insoluble material were cleared, protein content was measure by BCA Protein Assay and Tris / Glycine gels were run. Proteins w ere dry transferred, blocked with Intercept (Licor) blocking buffer, incubated w ith primary antibody overnight, and imaged using AlexaFluor secondary’ antibodies and the Odyssey system (Licor).Quantification was done using the Licor analysis software. Antibodies used were ERG (ab92513) and Vinculin (7F9 Invitrogen). Certain results were presented in Figure 13. In Figure 12, the following DC50 values were observed for reduction of ERG polypeptide levels in VCaP cells: Agent 3: 5 nM; Agent 4:>10000 nM; Agent 5: >10000 nM; Agent 6: 1200 nM. Among other things, provided technologies can reduce levels of ERG polypeptide.
[0215] In some embodiments, an effect of a provided technology may be dependent on proteosome. In some embodiments, an effect of a provided technology may be modulated by a proteosome inhibitor. In some embodiments, an effect of a provided technology may be dependent on the presence of an sufficient level of E3 ligase. In some embodiments, an effect of a provided technology may be modulated by another E3 ligand. For example, in an assessment VCaP cells w ere plated and treated the next day with 5 pM bortezomib or 1 pM E3-ligand. After a 1 h pretreatment, they were treated for 24 h w ith 100 nM agent. Certain observations are provided in Figure 14 and Figure 15. Among other things, reduction of ERG expression levels may be reduced by the presence of a proteosome inhibitor or an E3 ligand.
[0216] Among other things, provided technologies can selectively reduce ERG polypeptide levels. In some embodiments, proteomics technologies are utilized to, e.g., assess selectivity. A usefill experiment protocol is described below: VCaP cells were cultured for 24 hours in the presence of 1 pM agent or an Page 51 of 6713424615vlAttorney Docket Number: 2012675-0444equivalent volume of DMSO as a vehicle control. Cell pellets were collected and washed three times with PBS. Protein lysis and digestion were performed using tire PreOmics iST Sample Prep Kit (PreOmics).Samples were analyzed using a 60-minute gradient on a Vanquish Neo nano-LC system (Thermo Scientific). Data-independent acquisition (DIA) was carried out on an Orbitrap Exploris 480 mass spectrometer (Thenno Fisher) equipped with a nanospray ionization (NS1) source, operated in positive ion mode with a static spray voltage of +1900 V. The ion transfer tube temperature was set to 275 °C, and FAIMS was not employed. The method was optimized for liquid chromatography with an expected chromatographic peak width of 5 seconds. A single full-scan MSI event was acquired at a resolution of 120,000 over an m / z range of 300-985. This scan was followed by DIA MS2 scans covering a precursor m / z range of 300-900, using 50 isolation windows of 12 m / z width with 1 m / z overlap. Fragmentation was performed using higher energy collisional dissociation (HCD) with a normalized collision energy of 28%, and fragment ions were acquired at a resolution of 15,000. The MS2 scan range was set to m / z 145-1450. An RF lens setting of 70% was used. The automatic gain control (AGC) target was 1.0 x 106, and the maximum injection time was set to Auto. Raw data were analyzed using Spectronaut version 19.7.250203.62635, following the directDIA+ (Deep) workflow. Maximum-intensity m / z extraction was employed, local iRT calibration excluded deamidated peptides, and MS1 / MS2 mass tolerances followed system default settings. Among other things, provided technologies can reduce levels of ERG polypeptide without significant off-target changes in protein levels. Certain observations are presented in Figure 15.
[0217] In some embodiments, the present disclosure provides technologies for assessing pharmacokinetic and pharmacodynamic properties, and in vivo activities of agents described herein. In some embodiments, pharmacokinetic and pharmacodynamic properties, and various activities of provided technologies are assessed and confinned in vivo. For example, provided technologies can be assessed in CDX and PDX models. In an assessment, VCaP cells (ATCC CRL-2876) were implanted subcutaneously at the right flank at 10xl06cells / mouse in 1: 1 PBS: Reduced-Growth Factor Matrigel mixture in male NSG (NOD. Cg-Prkdcscid I12rgtmlWjl / SzJ) mice (Jackson Laboratory) 6-8 weeks old. For PK and PD studies, mice with tumors collectively averaging 350-500 mm3were put into groups using simple randomization. For assessing efficacy, mice underwent randomization once the tumors reached 150 mm3-250 mm3. Mice were dosed intravenously through tail vein injection with equal volume of vehicle. Vehicle was aqueous 10% DMSO, 20% PEG400, 13% PG, 30 mM Tris, pH adjusted to about 8. PK plasma samples were collected at indicated time points after 2nddose. PK was measured from plasma and tumor by standard bioanalytical methods. Among other things, provided agents delivered intravenously can distribute to xenograft tumors in vivo. Certain observations are presented in the table below’ and in Figure 17A and Figure 17B. Agent 3 was measured to be 0.21% free in mouse plasma in an assessment.Plasma TumorGroup Co (pg / mL) ti / 2 (h) AUC(0-264) C24(pg / mL) AUC(24-264)Page 52 of 6713424615vlAttorney Docket Number: 2012675-0444(h*pg / mg) (h* pg / mL) Agent 3, 1575.5 122 1459 6.66 1202 mg / kg q4dx2Agent 3, 1571.1 69.8 1490 4.63 1040 mg / kg q7dx2Agent 3, 7.588.6 73.5 947 3.60 541 mg / kg q4dx2Agent 4, 15160 NR, Rsq< 0.9 1797 6.45 1126 mg / kg q4dx2
[0218] Tumor samples were collected at indicated time points after 2nddose. ERG levels in tumor were measured by western blot as described above. Among other things, provided technologies can reduce ERG polypeptide levels in vivo. Certain observations are provided in Figure 18. ARHGDIB levels in tumor were measured by qPCR as described above. Among other things, provided technologies can reduce expression of ERG target gene, e.g., ARHGDIB, in vivo. Certain observations are provided in Figure 19.
[0219] Tumor volumes were measured twice per week after randomization in two dimensions using a digital caliper, and the volume was expressed in mm3using the formula: V = (L x W x W) / 2, where V is tumor volume, L is tumor length (the longest tumor dimension) and W is tumor width (the longest tumor dimension perpendicular to L). Body weight was measured and recorded twice a week to ensure the mice did not lose >10% BW, animals exhibiting >10% weight loss when compared to Day 0 were provided DietGel® ad libitum, along with all animals in the group. Any animal exhibiting >20% net weight loss for a period lasting 7 days or >30% net weight loss when compared to Day 0 were considered moribund and euthanized.
[0220] Study continued until the vehicle tumors reached 1500 mm3. Tumor grow th inhibition was calculated by the formula: Tumor Growth Inhibition: Mean % A Inhibition = (Ci -Co) -(Ti -To) / (Ci-Co)x100%; Ti and C, were the mean tumor volumes of the treatment and control groups, respectively, on a given day. To and Co were the mean tumor volumes of the treatment and vehicle groups on Day 0. For the hypogonadal efficacy study, male mice with VCaP tumors were castrated at around 1 0 mm3and allowed to recover for 7 days (tumors were 250-350 mm3) before treatments began. At least 3 mice were included for each time point in each group. Among other things, provided technologies can inhibit tumor grow th in vivo. Certain observations are provided in Figure 20 (for eugonadal mice with VCaP CDX tumors) and in Figure 22 (for VCaP CDX hypogonadal mice). ERG levels in tumor samples were measured by western blot as described above. Among other things, provided technologies can reduce ERG polypeptide levels in vivo. Certain observations are provided in Figure 21 (for VCaP CDX eugonadal mice) and in Figure 23 (for VCaP CDX hypogonadal mice).
[0221] Among other things, provided technologies can demonstrate activity in vivo in PDX mousePage 53 of 6713424615vlAtorney Docket Number: 2012675-0444model. In an assessment, warm pre-study tumor sections were implanted subcutaneously at the left flank in male NOG (NOD / Shi-scid / IL-2Rynull) mice (Taconic) 6-8 weeks old. Mice underwent randomization once the tumors reached 150-300 mm3. Mice were dosed intravenously through tail vein injection with equal volume of vehicle. Vehicle was aqueous 10% DMSO, 20% PEG400, 13% PG, 30 mM Tris, pH adjusted to about 8. Tumor volumes were measured twice per week after randomization in two dimensions using a digital caliper, and the volume was expressed in mm3using the formula: V = (L x W x W)*0.52, where V is tumor volume, L is tumor length (the longest tumor dimension) and W is tumor width (the longest tumor dimension perpendicular to L). Bodyweight was measured and recorded twice a week to ensure the mice were not losing >10% BW. Animals exhibiting >10% weight loss when compared to Day 0 were provided DietGel® ad libitum, along with all animals in the group. Any animal exhibiting >20% net weight loss for a period lasting 7 days or >30% net weight loss when compared to Day 0 were considered moribund and euthanized. Study continued until the vehicle tumors reached 1500 mm3. Tumor growth inhibition was calculated by the formula: Tumor Growth Inhibition: Mean % A Inhibition = (Ci -Co) -(Ti -To) / (C,-Co)x 100%; Ti and C, were the mean tumor volumes of the treatment and control groups, respectively, on a given day. To and Co ere the mean tumor volumes of the treatment and vehicle groups on Day 0. At least 4 mice were included in each group. Among other things, provided technologies can inhibit tumor growth in vivo. Certain observations are provided in Figure 24. ERG levels in tumor samples were measured by western blot as described above. Among other things, provided technologies can reduce levels of ERG polypeptide in vivo. Certain observations are provided in Figure 25.
[0222] In some embodiments, polypeptide levels are assessed by IHC. For example, to assess ERG levels in tumors, VCaP tumors w ere fixed 24 h in formalin and then moved to 70% isopropanol before making FFPE blocks. Blocks were cut 4-5 pm thickness and mounted onto Fisher Superfrost positively-charged glass slides. They were air dried overnight and bake on Leica BOND III IHC staining platform for 30 min at 60 °C prior to testing. Tissue sections were dewaxed using the Leica dew ax protocol on the BOND III platform with Leica’s BOND dewax solution. Antigen retrieval used Bond epitope retrieval 1 (ER1) solution (Leica AR9961), 20 min @ 100 °C, then Proteinase K (Agilent S302080-2) (diluted 1:40 in TBS buffer (Discovery 300010) for 10 min @ 37 °C, then Leica peroxidase block.
[0223] IHC detection was automated at room temperature on the BOND III platform. ERG primary antibody ATL1G (Cell Signaling 97249S) was diluted to 3 pg / mL in Reagent Manufacturing Buffer with goat serum (Discovery7400001) and incubated for 15 minutes. Primary7antibody was visualized using reagents from the BOND Polymer Refine Detection kit (Leica): application of HRP enzyme (8 min) in combination with DAB chromogen (10 min). Nuclei were counterstained using hematoxylin (5 min).
[0224] Slides were rinsed in distilled water and dehydrated in 95%. 100% ethanol series and in organic solvent (100% xylene, four changes). After dehydration, slides were permanently cover-slipped using a nonaqueous mounting media and viewed under 40x microscopy. Among other things, provided technologies can reduce levels of ERG polypeptides in vivo. Certain observations are provided in Figure 26.Page 54 of 6713424615vlAttorney Docket Number: 2012675-0444
[0225] Among other things, provided technologies can modulate cell cycle. In one assessment, VCaP cells were treated 48 h with vehicle, agent, and optionally 10 nM DHT. A standard method for analyzing Gl, S, G2 subpopulations of cells via FxCycle Violet (total dsDNA content) (ThennoFisher Fl 0347) vs EdU incorporation (newly-synthesized DNA) was used. Cells were incubated for 2 h with 10 pM EdU. Cells were collected by TrypLE, quenched with Flow Cytometry buffer (1% BSA in PBS). Cells were washed, fixed in 1% PFA, permeabilized, and redistributed in separate tubes for staining. Unstained controls as w'ell as EdU only and FxCycle only were created as well as EdU + FxCycle. Click-IT was used to detect EdU. 100,000 cells were analyzed per treatment by flow cytometry. Among other things, provided technologies can reduce S-phase population of cells in a system and / or provide cell cycle arrest at Go / Gi. Certain observations are provided in Figure 27.
[0226] Among other things, provided technologies can modulate nucleic acid expression. In some embodiments, provided technologies can modulate expression of ERG target genes. Various technologies can be utilized to assess gene expression in accordance with the present disclosure, e.g., qPCR, RNA sequencing, etc. In an assessment, RNA extracted using RNcasy kits (Qiagen) from endpoint efficacy tumors was processed by Next Generation mRNA sequencing using Poly (A) selection library preparation, 30 million reads per sample, on an Illumina NovaSeq. Prior to alignment, reads were preprocessed to remove adapter sequences, check for sequence quality, and filter non-tumor reads. A command-line tool cutadapt (Martin, M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet.journal 17, 10-12 (2011).) was used to trim paired-end reads for quality (“-q 20,20”), establish an error rate of 0.03 (-e “0.03”), and to remove reads shorter than 32 base pair long (“-minimum-length 32”). Adapter sequences w ere then trimmed by setting the “-a” and “-A” parameters to the universal Illumina adapter sequences (“-a AGATCGGAAGAG -A AGATCGGAAGAG”).
[0227] After reads were trimmed for quality and adapter sequences, they were additionally processed using xengsort (Zentgraf, J. & Rahmann, S. Fast lightweight accurate xenograft sorting. Algorithms Mol. Biol. 16, 2 (2021).) to separate tumor and mouse derived reads. To begin read filtering, the xengsort index was created using the “xengsort index” command. The mouse genome GRCm38 and the human genome GRCh38 were used as the host and graft genomes, respectively. Default parameters were used for xengsort index creation, with the exception of “-n 4 500 000 000” and subtables 9". After index creation, host reads were removed using the “xengsort classify” command passing the “-filter" argument.
[0228] Once mouse reads had been removed from samples, tumor-derived reads were aligned to GRCh38 using the STAR aligner (Dobin, A. el al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15-21 (2013).). Both index creation and read alignment were done using default parameters. After reads were aligned to the reference genome, PCR duplicates were identified using picard (Picard toolkit. Broad Institute. GitHub repository (2019).). Once BAM files had been generated and processed, read alignments were quantified using featureCoun ts (Liao, Y., Smyth, G. K. & Shi, W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 30, 923-930 (2014).) to Page 55 of 6713424615vlAttorney Docket Number: 2012675-0444generate raw counts for gene expression measures. featureCounts was run with default parameters with reads being quantified on per-gene-id basis using the “-g gene id” flag.
[0229] Differential expression analysis was performed using the edgeR (Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139-140 (2010).) package in the R programming language (R Core Team. R: A Language and Environment for Statistical Computing. (R Foundation for Statistical Computing, Vienna, Austria, 2023).), version 4.3.1. For differential expression analysis, samples were isolated to their respective model and hormonal groups for batched analysis. Specifically, all PDX samples were analyzed independently of CDX samples, and CDX samples were further isolated into eugonadal, pre inoculation, and post inoculation groups. The following differential expression protocols was then perfonned uniformly across all sample groups. Prior to performing differential expression analysis, counts were preprocessed and normalized following standard edgeR practices: genes with fewer than 5 counts across samples were removed; sample normalization factors were calculated using the edgeR:.calcNormFactors function; and gene dispersions were estimated using the edgeR:. -estimate Disp function, with the provided design matrix annotating vehicle, dose level 1, and dose level 2 sample groups. Certain sample and treatment groups are detailed in the table below.CDX / PDX Model Mouse Treatment Dosing Dose (mL / kg Sample Group Dose Name Frequency or mg / kg) Level CDX VCaP Eugonadal Vehicle q4d 10 VCaP CDX 0EugonadalCDX VCaP Eugonadal Agent 3 q4d 15 VCaP CDX 2EugonadalCDX VCaP Eugonadal Agent 3 q4d 7.5 VCaP CDX 1 EugonadalCDX VCaP Eugonadal Agent 4 q4d 15 VCaP CDX 1EugonadalCDX VCaP Castrated (post Vehicle q4d 10 VCaP CDX 0inoculation) Castrated (post inoculation)CDX VCaP Castrated (post Agent 3 q4d 15 VCaP CDX 2inoculation) Castrated (post inoculation)CDX VCaP Castrated (post Agent 3 q4d 7.5 VCaP CDX 1inoculation) Castrated (post inoculation)CDX VCaP Castrated (post Agent 4 q4d 15 VCaP CDX 1inoculation) Castrated (post inoculation)CDX VCaP Castrated (pre Vehicle q4d 10 VCaP CDX 0inoculation) Castrated (pre inoculation)CDX VCaP Castrated (pre Agent 3 q4d 15 VCaP CDX 2inoculation) Castrated (pre inoculation)CDX VCaP Castrated (pre Agent 3 q4d 7.5 VCaP CDX 1inoculation) Castrated (preinoculation)Page 56 of 6713424615vlAttorney Docket Number: 2012675-0444CDX VCaP Castrated (pre Agent 4 q7d 15 VCaP CDX 1 inoculation) Castrated (pre inoculation)PDX mCRPC Eugonadal Vehicle q4d 10 mCRPC PDX 0EugonadalPDX mCRPC Eugonadal Agent 3 q4d 15 mCRPC PDX 1 EugonadalPDX mCRPC Eugonadal Agent 3 q7d 15 mCRPC PDX 2Eugonadal
[0230] After count normalization and dispersion estimation, an edgeR general linear model was fit using edgeR::glmFit with the additional parameter ‘“robust = TRUE". Differential expression statistics were then calculated for each pairwise comparison using the edgeR::glmLRT function with default parameters. For each sample group, pairwise comparisons were made between treatments (i.e. vehicle control. Agent 3, Agent 4) and dose levels (above table). Once p-values and log2 foldchanges were calculated by edgeR, each gene was prescribed an activity score using the formula below.scoret= -log10(Pi) • lfct
[0231] Gene Set Enrichment Analysis: Following differential expression analysis, genes were ranked according to their newly calculated activity score, such that the most highly down-regulated genes would occupy low ranks, while the most highly up-regulated genes would occupy the highest ranks. Pre-ranked gene set enrichment analysis was then performed using the gseapy. prerank function with default parameters from the gseapy (Fang, Z., Liu, X. & Peltz, G. GSEApy: a comprehensive package for performing gene set enrichment analysis in Python. Bioinformatics 39, btac757 (2023).) Python package (Python version 3.12.3, gseapy version 1.1.7). Enrichment analysis was perfonned over the Hallmark gene sets from MSigDB (Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles | PNAS. Mootha, V. K. et al. PGC- la-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet. 34, 267-273 (2003).). This analysis was repeated for each differential expression comparison perfonned across treatment and sample groups. Gene sets were considered significantly enriched when adjusted fdr 0.05. Among other things, Hallmark_MycTargets_V2 was identified for various CDX and PDX models (e.g.. eugonadal VCaP CDX, hypogonadal VCaP CDX, mCRPC PDX, etc.), and it was confirmed that provided technologies can reduce levels of Myc target genes.
[0232] Among other things, provided technologies can provide various activities. In some assessments, provided agents can bind strong to an ERG polypeptide when measured using SPR. In some assessments, provided agents demonstrated activities when assessed using ERG HiBiT assay. In some assessments, certain agents showed certain levels of activity when assessed in a FLU HiBiT assay. In some assessments, certain agents showed more activity than others. In some assessments, provided agents reduced ERG target gene expression (e.g., ARHGDIB). In some assessments, provided agents reduced proliferation. Various assessments were conducted using VCaP cells. In some assessments, proteomics for cells treated with provided technologies suggests high selectivity for ERG degradation over other proteins in REH (express Page 57 of 6713424615vlAttorney Docket Number: 2012675-0444both ERG and FLU), VCaP (express ERG), and PC3 cells (do not express ERG or FLU). It was observed that at least in some assessments, most of the significantly changed proteins in VCaP cells were ERG and its target genes. In some assessments, it was observed that reduction of ERG polypeptide levels was proteasome and E3 ligase dependent. In some assessments, some agents demonstrated more selectivity for ERG over FLU than others. In some embodiments, the present disclosure provides technologies for improving solubility without significantly reducing ERG degradation capability. In some assessments, certain agents can be subcutaneously administered to achieve certain PK profiles and target engagement.
[0233] In some assessments, provided technologies reduced cell grow th, c.g., in a colony formation assay. In some assessments, provided technologies showed cell cycle arrest demonstrated by a reduction in proliferating (S and G2) cells with ERG degrader treatment and an increase in the sub-Gi population. In some assessments, provided technologies reduced Myc polypeptide levels. Various assessments were conducted in VCaP cells.
[0234] PK / PD of a provided agent suggested dose-dependent ERG degrader activity in VCaP CDX. In some assessments, useful plasma concentration profile w as observed for a provided agent. In some assessments, it w as observed that plasma concentration was correlated w ith ERG degradation, and dosing schedule suppressed ERG below 90% of baseline levels persistently throughout treatment, in a model system. Reduction of ERG target gene expression, e.g., ARHGDIB, was also observed. In some assessments, agents were assessed in the models below”Intact / TumorHarvest Site Mutations Prior Therapies Castrated TypeMouse Goserelin acetate and flutamide, 9-amino- TMPRSS2-ERG, ARAdeno Bone CPT, paclitaxel / estramustine / etoposide, Both amplification, p53 mutcyclophosphamide / prednisoneTMPRSS2-ERG, ARLeuprolide / Sipuleucel-T (NR),Adeno CTC amplification, DDR Intact Enzalutamide / Docetaxel (NR)mutationsTMPRSS2-ERG, AR Bicalutamide / Leuprolide (R), Sipuleucel- Adeno Bone amplification, ATM mut, T, Enzalutamide, Abiraterone, Docetaxel Intact PTEN + / - (R), Radium-223, Cabazitaxel (NR)Bicalutamide / Leuprolide (2 rounds),TMPRSS2-ERG, ARAdeno Bone Experimental androgen / progesterone Intact W742C, PTEN+ / - blocker, EnzalutamideTMPRSS2-ERG, AR+.Adeno Lymph node Androgen Ablation and DES Intact p53 mut. PTEN - / -Page 58 of 6713424615vlAttorney Docket Number: 2012675-0444TMPRSS2-ERG, AR+, ketoconazole, corticosteroid, DocetaxelAdeno Bone Both p53 deletion, PTEN - / - (R), Enzalutamide (NR)1stgeneration ADT; Local radiation +leuprolide + bicalutamide +TMPRSS2-ERG, AR+ ketoconazole; docetaxel + estramustine;Adeno Bone Intact mut; p53 mut; PTEN- / - thalidomide + paclitaxel + estramustine;+ 4 rounds of chemotherapies +MAPK / DDR therapiesLocal radiation + hormone therapy;TMPRSS2-ERG, Rb- / -;leuprolide; docetaxel + carboplatin;NE Bladder PTEN- / -; p53 mut; NRAS Intact etoposide + cisplatin, 1st GenerationQ61KADTIn some assessments, it was observed that ERG levels at baseline did not correlate with maximum efficacy (Tumor Growth Inhibition % (TGI%)) of ERG degrader agents (R2= 0.17) (e.g., for a neuroendocrine model, low baseline ERG and low max efficacy), and the level of ERG degradation, as measured by Western blot at end of study, correlates well with TGI across CDX and PDX models (R2= 0.59) (e.g., for a neuroendocrine model, ERG protein high and low efficacy), indicating ERG dependency across models. In some assessments, for certain agents it was observed that anti-tumor efficacy correlated to ERG degradation in several PDX models from differing genetic backgrounds and with different patient treatment histories. In some assessments, efficacy was observed in ERG-fusion+mCRPC AR amplified CDX and / or PDX models. In some assessments, no activity was observed in an ERG / AR low neuroendocrine model. In some assessments, ERG degradation decreased tumor growth by promoting differentiation. In some assessments, level of a differentiation marker, e.g., KRT8, KRT18, CD44, LGALS3, etc. was increased. In some embodiments, the present disclosure provides a method for increasing level of a differentiation marker, e.g., KRT8, KRT18, CD44, LGALS3, etc. in a system, comprising administering or delivering to the system a provided agent. In some assessments, level of apoptosis maker, e.g., cleaved caspase 3, was increased. In some embodiments, the present disclosure provides a method for increasing level of an apoptosis marker, e.g., cleaved caspase 3, in a system, comprising administering or delivering to the system a provided agent. In some assessments, level of a proliferation marker, e.g., Ki67, c-Myc, etc. was reduced. In some embodiments, the present disclosure provides a method for reducing level of a proliferation marker, e.g., Ki67, c-Myc, etc. in a system, comprising administering or delivering to the system a provided agent.
[0235] Certain combinations of ERG degraders with enzalutamide (AR pathway inhibitor) or PRC2 inhibitor were assessed and was observed to promote apoptosis in VCaP cells. A. It was observed that VCaP cells become more sensitive to a provided agent when treated with a fixed concentration of enzalutamide orPage 59 of 6713424615vlAttorney Docket Number: 2012675-0444PRC2 inhibitor. In some assessments, it was observed combination with an ARPI or a PRC2 inhibitor can increase percentage of early apoptosis, or late apoptosis and / or necrosis. In some assessments, it was observed that the total percentage of early apoptosis, late apoptosis and necrosis were increased by the combination. It was also observed that polypeptide levels of apoptosis marker cleaved PARP1 showed higher apoptosis in combination treatments. In some embodiments, ERG degraders may combine well with SOC AR pathway inhibitors and / or other epigenetic target inhibitors such as PRC2 (EZH2 / EED), to limit proliferation and promote apoptosis.
[0236] While various embodiments have been described and illustrated herein, those of ordinary’ skill in the art will readily envision a variety of other means and / or structures for performing the functions and / or obtaining the results and / or one or more of the advantages described in the present disclosure, and each of such variations and / or modifications is deemed to be included. More generally, those skilled in the art will readily appreciate that all parameters, dimensions, materials, and configurations described herein are meant to be example and that the actual parameters, dimensions, materials, and / or configurations will depend upon the specific application or applications for which the teachings of the present disclosure is / arc used. Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the disclosure described in the present disclosure. It is, therefore, to be understood that the foregoing embodiments are presented by way of example only and that, provided technologies, including those to be claimed, may be practiced otherwise than as specifically described and claimed. In addition, any combination of two or more features, systems, articles, materials, kits, and / or methods, if such features, systems, articles, materials, kits, and / or methods are not mutually inconsistent, is included within the scope of the present disclosure.
[0237] The present disclosure incorporates various information, including patent application publications, patents and non-patent references, by reference; in the case of any conflict, the present disclosure controls.Page 60 of 6713424615vl
Claims
1. Attorney Docket Number: 2012675-0444CLAIMS1. An agent, wherein the agent has the structure of:TBM-L°-LBM,or a salt thereof, wherein:TBM is a target binding agent that can bind ERG:L° is a linker, or a covalent bond or an optionally substituted, bivalent C1-C30 aliphatic or heteroaliphatic group having 1-12 heteroatoms, wherein one or more methylene units of the group are each optionally and independently replaced with -C(R’)2-, -Cy-, -O-, -S-, -S-S-, -N(R’)-, -C(O)-, -C(S)--C(NR’)-, -C(O)N(R’)-, -N(R’)C(O)N(R )-, -N(R )C(O)O-, -S(O)-, -S(O)2-, -S(O)2N(R’)-, -C(O)S--C(O)O-, -(OCH2CH2)n-, or an amino acid residue;n is 1-20;LBM is an E3 ligase binding moiety;each -Cy- is independently an optionally substituted bivalent 3-30 membered ring having 0-10 hctcroatoms;each R’ is independently -R, -C(O)R, -CO2R, or -SO2R: andeach R is independently -H, or an optionally substituted group selected from C1.30 aliphatic. C1-30 heteroaliphatic having 1-10 heteroatoms, Ce-so aryl, Ce-so arylaliphatic, Ce-3o arylheteroaliphatic having 1-10 heteroatoms, 5-30 membered heteroaryl having 1-10 heteroatoms, and 3-30 membered heterocyclyl having 1-10 heteroatoms; ortwo R groups are optionally and independently taken together to form a covalent bond; or two or more R groups on the same atom are optionally and independently taken together with the atom to form an optionally substituted, 3-30 membered ring having, in addition to the atom, 0-10 heteroatoms; ortwo or more R groups on two or more atoms are optionally and independently taken together with their intervening atom(s) to form an optionally substituted, 3-30 membered ring having, in addition to the intervening atom(s), 0-10 heteroatoms.
2. The agent of claim 1, wherein the E3 ligase is CRBN, VHL. UBR4, KLHDC2, KEAP1. XIAP, or RNF126.
3. The agent of any one of the preceding claims, wherein the E3 ligase is CRBN.
4. The agent of any one of the preceding claims, wherein the E3 ligase is VHL.
5. The agent of any one of the preceding claims, wherein L° is an optionally substituted, bivalent C1-C30 aliphatic or heteroaliphatic group having 1-12 heteroatoms, wherein one or more methylene units of the group are each optionally and independently replaced with -C(R’)2-, -Cy-. -O-, -S-, -S-S-, -N(R’)-, -C(O)-. -C(S)-, -C(NR’)-, -C(O)N(R')-. -N(R')C(O)N(R’)-, -N(R’)C(O)O- -S(O)-, -S(O)2--S(O)2N(R’)-, -C(O)S- — C(O)O—, -(OCH2CH2)n-, or an amino acid residue.
6. The agent of any one of the preceding claims, wherein TBM is or comprises -[PTBM], wherein PTBMisPage 61 of 6713424615vlAttorney Docket Number: 2012675-0444or comprises a stapled peptide.
7. Tire agent of any one of the preceding claims, wherein PTBMcomprises:[X]pX1X2X3X4X5X6X7X8X9X10[X11]p1i[X12]pi2[X13]pi3[X,4]pi4[X15]p15[X16]pi6[X17]pi7[X,8]pi8[X]p-, wherein:each of pl 1, pl2, p 13, pl4, p 15, pl6, pl7 andpl8 is independently 0 or 1;each of p and p’ is independently 0- 10; andeach of X, X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12, X13, X14, X15, X16, X17and X18is independently an amino acid residue.
8. An agent, wherein the agent is or comprises:[X]pX1X2X3X4X5X6X7X8X9X10[X1,]p11[X12]p12[X,3]pl3[X14]p14[X15]p15[X16]p16[X,7]pl7[X18]p18[X]p-, wherein:each of pl 1, pl2, p 13, pl4, p 15, pl6, pl7 and pl8 is independently 0 or 1;each of p and p’ is independently 0-10; andeach of X, X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12, X13, X14, X15, X16, X17and X18is independently an amino acid residue.
9. The agent of any one of claims 7-8, wherein one or more of X1, X2, X3, X4, X5, X6, X7, X8, X9, X1", X11, X12, X13, and X14are each independently a D-amino acid residue.
10. The agent of any one of claims 7-8, wherein each of X1, X2, X3, X4, X’, X6, X7, X8, X9, X10, X11, X12, X13, and X14is independently a D-amino acid residue.
11. Hie agent of any one of the preceding claims, wherein L° is bonded to X1.
12. The agent of any one of claims 7-10, wherein L° is bonded to X\13. The agent of any one of claims 7-10, wherein L° is bonded to X7.
14. The agent of any one of claims 7-10, wherein L° is bonded to Xs.
15. The agent of any one of claims 7-10, wherein L° is bonded to X13.
16. The agent of any one of the preceding claims, wherein the agent is capable of binding to ERG selectively.
17. The agent of any one of the preceding claims, wherein the agent is capable of binding to ERG with a KD about or no more than about 100, 10. 5 or 1 nM.
18. The agent of any one of the preceding claims, wherein the agent is capable of binding to an E3 ligase with a KD about or no more than about 100, 10, 5 or 1 nM.
19. The agent of any one of the preceding claims, wherein the agent can reduce ERG polypeptide level in cells.
20. The agent of claim 19. wherein the reduction by the agent of ERG polypeptide levels in cells is reduced in the presence of a proteosome inhibitor.
21. The agent of claim 20, wherein the proteosome inhibitor is bortezomib.
22. The agent of claim 19, wherein the reduction by the agent of ERG polypeptide levels in cells is Page 62 of 6713424615vlAttorney Docket Number: 2012675-0444reduced in the presence of an E3 Ligand.
23. Tire agent of claim 19, wherein ERG can be degraded with low nanomolar potency.
24. The agent of any one of the preceding claims, wherein the agent can reduce ERG polypeptide level in cells without significant reduction of the level of most or any other polypeptides.
25. The agent of any one of the preceding claims, wherein the agent can inhibit tumor growth when assessed in a VCaP xenograft mouse model.
26. The agent of any one of the preceding claims, wherein tire agent can reduce ERG polypeptide level when assessed in a cugonadal VCaP CDX model.
27. The agent of any one of the preceding claims, wherein the agent can reduce ERG polypeptide level when assessed in a hypogonadal VCaP CDX model.
28. The agent of any one of the preceding claims, wherein the agent can reduce ERG polypeptide level when assessed in a metastatic castration resistant prostate cancer (mCRPC) PDX model.
29. The agent of any one of the preceding claims, wherein tire agent can reduce ERG polypeptide level when assessed in a cugonadal metastatic castration resistant prostate cancer (mCRPC) PDX model.
30. The agent of any one of the preceding claims, wherein the agent can reduce ERG polypeptide level when assessed in a eugonadal VCaP CDX model.
31. The agent of any one of the preceding claims, wherein the agent can reduce ERG polypeptide level when assessed in a hypogonadal VCaP CDX model.
32. The agent of any one of the preceding claims, wherein tire agent can reduce ERG polypeptide level when assessed in a metastatic castration resistant prostate cancer (mCRPC) PDX model.
33. The agent of any one of the preceding claims, wherein the agent can reduce ERG polypeptide level when assessed in a eugonadal metastatic castration resistant prostate cancer (mCRPC) PDX model.
34. The agent of any one of the preceding claims, wherein the agent can bind to the ETS domain of ERG.
35. The agent of any one of the preceding claims, wherein the agent can bind to the PNT domain of ERG.
36. Tire agent of any one of the preceding claims, wherein the agent can bind to a polypeptide that is or comprises a full-length ERG.
37. The agent of any one of the preceding claims, wherein the agent can bind to a polypeptide that is or comprises a TMPRSS2-ERG fusion protein.
38. The agent of any one of the preceding claims, wherein tire agent can provide cell cycle arrest.
39. A composition comprising an agent of any one of the preceding claims or a salt thereof.
40. A pharmaceutical composition, comprising or delivering an agent of any one of the preceding claims, and a pharmacally acceptable carrier.
41. A method for reducing ERG polypeptide level in a system, comprising administering or delivering to the system an agent or composition of any one of the preceding claims.
42. A method for increasing ubiquitination of an ERG polypeptide in a system, comprising administering Page 63 of 6713424615vlAttorney Docket Number: 2012675-0444or delivering to the system an agent or composition of any one of the preceding claims.
43. A method for reducing cell proliferation in a system, comprising administering or delivering to the system an agent or composition of any one of the preceding claims.
44. A method for reducing cell invasion in a system, comprising administering or delivering to the system an agent or composition of any one of the preceding claims.
45. A method for reducing cell migration in a system, comprising administering or delivering to the system an agent or composition of any one of the preceding claims.
46. A method for reducing sternness of prostate cancer cells in a system, comprising administering or delivering to the system an agent or composition of any one of the preceding claims.
47. A method for providing cell cycle arrest in a system, comprising administering or delivering to the system an agent or composition of any one of the preceding claims.
48. A method for reducing S-phase population of cells in a system, comprising administering or delivering to tire system an agent or composition of any one of tire preceding claims.
49. A method for increasing population of cells in Go / Gi phase in a system, comprising administering or delivering to the system an agent or composition of any one of the preceding claims.
50. A method for modulating ERG target gene expression in a system, comprising administering or delivering to the system an agent or composition of any one of the preceding claims.
51. A method for modulating ARHGDIB expression in a system, comprising administering or delivering to the system an agent or composition of any one of the preceding claims.
52. A method for modulating Myc target gene expression in a system, comprising administering or delivering to the system an agent or composition of any one of the preceding claims.
53. A method for inhibiting tumor growth in a system, comprising administering or delivering to the system an agent or composition of any one of the preceding claims.
54. The method of any one of claims 41-53, wherein a system is an in vitro system.
55. The method of any one of claims 41-53, wherein a system is an in vivo system.
56. Hie method of any one of claims 41-53, wherein a system is or comprises a sample.
57. The method of any one of claims 41-56, wherein a system is or comprises a cell, tissue or organ.
58. The method of any one of claims 41-57. wherein a system is or comprises cancer cells.
59. The method of any one of claims 41-58, wherein a system is or comprises prostate cancer cells.
60. The method of any one of claims 41-59, wherein a system is or comprises castration resistant prostate cancer (CRPC) cells.
61. Tire method of any one of claims 41-60, wherein a system is or comprises metastatic castration resistant prostate cancer (mCRPC) cells.
62. The method of any one of claims 41-61. wherein a system is or comprises ERG fusion metastatic castration resistant prostate cancer cells.
63. The method of any one of claims 41-62, wherein a system is or comprises VCaP cells.Page 64 of 6713424615vlAttorney Docket Number: 2012675-044464. The method of any one of claims 41-63, wherein a system is or comprises a tumor.
65. Tire method of any one of claims 41-64, wherein a system is or comprises a VCaP xenograft model.
66. The method of any one of claims 41-62, wherein a system is or comprises a mCRPC xenograft model.
67. The method of any one of claims 41-66, wherein a system is a subject.
68. The method of any one of the preceding claims, wherein the system comprises ERG fusion.
69. The method of any one of the preceding claims, wherein the system comprises aberrant TMPRSS2- ERG fusion.
70. A method for treating or preventing a condition, disorder or disease associated with ERG in a subject, comprising administering or delivering to the subject an agent or composition of any one of the preceding claims.
71. A method for treating a condition, disorder or disease in a subject, comprising administering or delivering to tire subject an agent or composition of any one of the preceding claims.
72. Tire method of claim 71, w herein the condition, disorder or disease is associated w ith or characterized by an ERG mutation.
73. The method of claim 71, wherein the condition, disorder or disease is associated with or characterized by ERG overexpression.
74. The method of any one of claims 70-73, wherein the subject has an ERG fusion mutation.
75. The method of any one of claims 70-74, wherein the subject has aberrant TMPRSS2-ERG fusion.
76. Tire method of any one of claims 70-75, wherein the condition, disorder or disease is cancer.
77. The method of any one of claims 70-76, wherein the condition, disorder or disease is prostate cancer.
78. The method of any one of claims 70-77. wherein tire condition, disorder or disease is metastatic prostate cancer.
79. The method of any one of claims 70-78, wherein the condition, disorder or disease is CRPC.
80. The method of any one of claims 70-79, wherein the condition, disorder or disease is metastatic CRPC.
81. The method of any one of claims 77-80, wherein a tumor of the prostate cancer comprises an ERG fusion mutation.
82. The method of any one of claims 77-80, wherein a tumor of the prostate cancer tumor comprises a TMPRSS2-ERG fusion mutation.
83. The method of any one of claims 77-80, wherein a cancer cell of the prostate cancer comprises an ERG fusion mutation.
84. The method of any one of claims 77-80, wherein a cancer cell of the prostate cancer tumor comprises a TMPRSS2-ERG fusion mutation.
85. The method of any one of the preceding claims, comprising administering or delivering to a subject a second therapy.Page 65 of 6713424615vlAttorney Docket Number: 2012675-044486. The method of claim 85, wherein a second therapy is or comprises an androgen deprivation treatment.
87. The method of any one of the preceding claims, comprising administering or delivering to a subject a second therapeutic agent.
88. The method of claim 87, wherein a second therapeutic agent is or comprises androgen receptor pathway inhibitor.
89. The method of claim 87, wherein a second therapeutic agent is or comprises androgen receptor antagonist.
90. The method of claim 87, wherein a second therapeutic agent is or comprises enzalutamide.
91. The method of claim 87, wherein a second therapeutic agent is or comprises apalutamide.
92. The method of claim 87, wherein a second therapeutic agent is or comprises darolutamide.
93. The method of claim 87, wherein a second therapeutic agent is or comprises abiraterone.
94. The method of claim 87, wherein a second therapeutic agent is or comprises ARV-110 (bavdcgalutamidc).
95. The method of claim 87, wherein a second therapeutic agent is or comprises ARV-766 (luxdegalutamide).
96. The method of claim 87, wherein a second therapeutic agent is or comprises BMS-986365 (gridegalutamide).
97. The method of claim 87, wherein a second therapeutic agent is or comprises GDC-2992.
98. Hie method of claim 87, wherein a second therapeutic agent is or comprises AZD 9750.
99. The method of claim 87, wherein a second therapeutic agent is or comprises an epigenetic target inhibitor (e.g., PRC2 (EZH2 / EED)).
100. The method of claim 87, wherein a second therapeutic agent is or comprises a PRC2 inhibitor.Page 66 of 6713424615vl
